<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Microbes Infect</journal-id><journal-id journal-id-type="iso-abbrev">Microbes Infect</journal-id><journal-title-group><journal-title>Microbes and Infection</journal-title></journal-title-group><issn pub-type="ppub">1286-4579</issn><issn pub-type="epub">1769-714X</issn><publisher><publisher-name>Institut Pasteur. Published by Elsevier Masson SAS.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7217786</article-id><article-id pub-id-type="publisher-id">S1286-4579(20)30083-6</article-id><article-id pub-id-type="doi">10.1016/j.micinf.2020.05.005</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Comparative review of respiratory diseases caused by coronaviruses and influenza A viruses during epidemic season</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Jiang</surname><given-names>Chao</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Yao</surname><given-names>Xingang</given-names></name><xref rid="aff3" ref-type="aff">c</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Zhao</surname><given-names>Yulin</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Wu</surname><given-names>Jianmin</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Huang</surname><given-names>Pan</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Pan</surname><given-names>Chunhua</given-names></name><email>chungenp@163.com</email><xref rid="aff4" ref-type="aff">d</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Liu</surname><given-names>Shuwen</given-names></name><email>liusw@smu.edu.cn</email><xref rid="aff3" ref-type="aff">c</xref><xref rid="cor2" ref-type="corresp">&#x02217;&#x02217;</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>Pan</surname><given-names>Chungen</given-names></name><email>chhpan@163.com</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor3" ref-type="corresp">&#x02217;&#x02217;&#x02217;</xref></contrib><aff id="aff1"><label>a</label>Laboratory of Molecular Virology &#x00026; Immunology, Technology Innovation Center, Haid Research Institute, Guangdong Haid Group Co., Ltd, Guangzhou, 511400, China</aff><aff id="aff2"><label>b</label>School of Life Sciences, Bengbu Medical College, Bengbu, Anhui, 233030, China</aff><aff id="aff3"><label>c</label>State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China</aff><aff id="aff4"><label>d</label>Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, 510000, China</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author. Affiliated Cancer Hospital and Institute of Guangzhou Medical University, No. 78, Heng Zhi Gang Road, Yuexiu District, Guangzhou, 510000, China. <email>chungenp@163.com</email></corresp><corresp id="cor2"><label>&#x02217;&#x02217;</label>Corresponding author. School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China. <email>liusw@smu.edu.cn</email></corresp><corresp id="cor3"><label>&#x02217;&#x02217;&#x02217;</label>Corresponding author. Haid Research Institute, Guangdong Haid Group Co., Ltd, 5 Eighth Street, Fu Ping Road, Guangzhou, 511400, China. <email>chhpan@163.com</email></corresp><fn id="fn1"><label>1</label><p id="ntpara0010">These authors contributed equally.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>13</day><month>5</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub" iso-8601-date="2020-08-01"><season>July-August</season><year>2020</year></pub-date><pub-date pub-type="epub"><day>13</day><month>5</month><year>2020</year></pub-date><volume>22</volume><issue>6</issue><fpage>236</fpage><lpage>244</lpage><history><date date-type="received"><day>8</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>11</day><month>5</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Institut Pasteur</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="abs0010"><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to sweep the world, causing infection of millions and death of hundreds of thousands. The respiratory disease that it caused, COVID-19 (stands for coronavirus disease in 2019), has similar clinical symptoms with other two CoV diseases, severe acute respiratory syndrome and Middle East respiratory syndrome (SARS and MERS), of which causative viruses are SARS-CoV and MERS-CoV, respectively. These three CoVs resulting diseases also share many clinical symptoms with other respiratory diseases caused by influenza A viruses (IAVs). Since both CoVs and IAVs are general pathogens responsible for seasonal cold, in the next few months, during the changing of seasons, clinicians and public heath may have to distinguish COVID-19 pneumonia from other kinds of viral pneumonia. This is a discussion and comparison of the virus structures, transmission characteristics, clinical symptoms, diagnosis, pathological changes, treatment and prevention of the two kinds of viruses, CoVs and IAVs. It hopes to provide information for practitioners in the medical field during the epidemic season.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Coronaviruses</kwd><kwd>Influenza A viruses</kwd><kwd>Transmission</kwd><kwd>Diagnosis</kwd><kwd>Therapy</kwd><kwd>Prevention</kwd></kwd-group></article-meta></front><body><p id="p0120">In December 2019, a novel coronavirus, SARS-CoV-2, caused a pneumonia epidemic in Wuhan, Hubei province of China. It erupted in many other countries in the following months and eventually became a worldwide pandemic. The pneumonia was officially named COVID-19 by World Health Organization (WHO) [<xref rid="bib1" ref-type="bibr">1</xref>]. So far, the pandemic is still accelerating. More than 4.3 million people were confirmed infected, 290,000 more people died globally [<xref rid="bib2" ref-type="bibr">2</xref>], and the virus transmission is expected to last for more than one year [<xref rid="bib3" ref-type="bibr">3</xref>]. At the same time, other types of coronaviruses and influenza viruses, which have been widespread in the world, may invade human society again during this winter or in other circumstances, circulating together with the SARS-CoV-2 and causing more serious respiratory diseases [<xref rid="bib4" ref-type="bibr">4</xref>,<xref rid="bib5" ref-type="bibr">5</xref>]. It is necessary to investigate whether the simultaneous prevalence of SARS-CoV-2 and other respiratory viruses, such as IAVs, can promote the spreading of each other. In addition, because the clinical symptoms caused by CoVs and IAVs infection are very similar to each other [<xref rid="bib6" ref-type="bibr">6</xref>], it will bring further challenges to clinicians in the timely diagnosis and treatment of patients. This article will summarize and compare the epidemic characteristics, clinical symptoms, treatment, and prevention measures for the diseases which are caused by CoVs or IAVs respectively, hoping to provide a brief comparative information for the clinicians and researchers who are working in the related fields.</p><sec id="sec1"><label>1</label><title>Viruses</title><p id="p0125">CoVs are enveloped, single strand positive-sense RNA viruses with a genome consisting of 26 to 32k nucleotides, expressing 16 nonstructural proteins (nsp1 to nsp16) and four structural proteins, such as spike (S protein), membrane, envelope, and nucleocapsid proteins [<xref rid="bib7" ref-type="bibr">7</xref>]. As shown in <xref rid="fig1" ref-type="fig">Fig.&#x000a0;1</xref>
A, S protein is located on the surface of virus particles, which plays a key role in virus entry into host cells, and is also one of the major targets of antiviral drugs and neutralizing antibodies [<xref rid="bib8" ref-type="bibr">[8]</xref>, <xref rid="bib9" ref-type="bibr">[9]</xref>, <xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>]. CoVs are divided into four genera which belongs to Coronaviridae, alpha, beta, delta and gamma CoVs. So far, there are seven CoVs causing human diseases, including three highly pathogenic CoVs (HPCoVs) (SARS-CoV-2, MERS-CoV, and SARS-CoV) and four normal human CoVs (abbreviated as HCoVs) (HCoV229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1) [<xref rid="bib12" ref-type="bibr">12</xref>]. HCoV-229E and HCoV-NL63 belong to the alpha genus, while the other 5 CoVs belong to the beta genus. The genes of S protein from the three HPCoVs form 3 clusters, as shown in the polygenetic tree in <xref rid="fig1" ref-type="fig">Fig.&#x000a0;1</xref>A. Compared with MERS-CoV, the S protein gene of SARS-CoV-2 is a little bit closer to SARS-CoV, as reported they are sharing about 50% identity [<xref rid="bib13" ref-type="bibr">13</xref>].<fig id="fig1"><label>Fig.&#x000a0;1</label><caption><p>Spike proteins and life cycles of CoV and IAV. 3D models of CoV with spike protein genes based polygenetic tree (A) and summary diagram of the CoV life cycle (B). (C) IAV with HA protein genes based polygenetic tree and (D) summary diagram of IAV life cycle. Both neighbor-joining trees are generated by using ClustalX 1.83 and MEGA7 with the full length of glycoprotein genes downloaded from GenBank. The year in the brackets indicates that the time of the virus was reported first.</p></caption><alt-text id="alttext0010">Fig.&#x000a0;1</alt-text><graphic xlink:href="gr1_lrg"/></fig></p><p id="p0130">CoVs replication only occurs in the cytoplasm. As show in <xref rid="fig1" ref-type="fig">Fig.&#x000a0;1</xref>B, virus binds to its receptor angiotensin-converting enzyme 2 (ACE2) (SARS-CoV-2, SARS-CoV, and HCoV-NL63), dipeptidyl peptidase-4 (DPP4) (MERS-CoV), 9-O-Acetylated sialic acid (HCoV-OC43), or human aminopeptidase N (CD13) (HCoV-229E) [<xref rid="bib14" ref-type="bibr">14</xref>], and entry into the cell by direct membrane fusion or endocytosis, in which the virus membrane fusing with cell membrane or endosome membrane and releasing viral RNA, then the virus positive-sense RNA was used as a template to synthesize negative-sense genomic RNA, this was template again to transcript mRNAs and also to replicate progeny positive-sense RNA. Viral proteins were translated by mRNAs through the endoplasmic reticulum and Golgi apparatus system for packaging into mature viral particles with the progeny RNA in the cytoplasm. Then the virions was transported to cell membrane and released by exocytosis [<xref rid="bib7" ref-type="bibr">7</xref>,<xref rid="bib15" ref-type="bibr">15</xref>].</p><p id="p0135">Similar to CoV, IAV is also an enveloped virus, with genome of a single strand but negative-sense RNA, which is divided into eight segments, encoding 12 proteins, including PB2, PB1, PB1&#x02013;F2, PB1 N40, PA, NP, HA, NA, M1, M2, NS, and NEP/NE2, respectively [<xref rid="bib16" ref-type="bibr">16</xref>]. As shown in <xref rid="fig1" ref-type="fig">Fig.&#x000a0;1</xref>C, haemagglutinin (HA) and neuraminidase (NA) are distributed on the surface of virus particles, which are the basis for subtype classification of IAVs and also play important roles during the process of virus invasion and mature virus releasing [<xref rid="bib17" ref-type="bibr">17</xref>,<xref rid="bib18" ref-type="bibr">18</xref>]. Like S protein of CoVs, HA and NA are very important targets of antiviral drugs and vaccines [<xref rid="bib19" ref-type="bibr">[19]</xref>, <xref rid="bib20" ref-type="bibr">[20]</xref>, <xref rid="bib21" ref-type="bibr">[21]</xref>]. In recent 30 years, three subtypes of IAVs, including H1N1pdm09 virus causing 2009 flu pandemic [<xref rid="bib22" ref-type="bibr">22</xref>], and two highly pathogenic avian viruses, H5N1 and H7N9 viruses, had caused severe respiratory diseases and resulted in thousands of deaths or high mortality in humans [<xref rid="bib23" ref-type="bibr">23</xref>,<xref rid="bib24" ref-type="bibr">24</xref>]. The majority subtype of seasonal IAVs is H3N2 [<xref rid="bib25" ref-type="bibr">25</xref>]. The polygenetic tree in <xref rid="fig1" ref-type="fig">Fig.&#x000a0;1</xref>C displays the three clusters of HA genes. They show a distinct difference from each other, with the HA gene of H5N1 virus generating more mutations during its transmission as reported [<xref rid="bib26" ref-type="bibr">26</xref>].</p><p id="p0140">Compared to CoV, there are two major differences in the life cycle of IAV. First, the IAV needs to replicate its genome in the nucleus. Secondly, the virions are released by assembly and budding from cellular membrane. As illustrated in <xref rid="fig1" ref-type="fig">Fig.&#x000a0;1</xref>D, IAV binds to receptor &#x003b1;-2,3-linked sialic acid (H7N9 and H5N1) or &#x003b1;2,6-linked sialic acid (H1N1 and H3N2) to form endosome and enters into cell, and the viral RNA was released into the cytoplasm by viral-endosome membrane fusion. Then the viral RNA is imported into the nucleus, and once there starts both virus RNA transcription and replication. After mRNAs and progeny negative-sense RNAs are exported to cytoplasm, the proteins are translated and trafficked to the cell membrane into packaged RNAs. The mature virus then buds from the cells [<xref rid="bib27" ref-type="bibr">27</xref>].</p></sec><sec id="sec2"><label>2</label><title>Transmission</title><p id="p0145">For the spread of viruses, there are no borders between countries as more and more interactions and cooperation were established worldwide. Since the CoVs and IAVs were identified as the major pathogens for respiratory diseases in last century, they have traveled to many corners of the world [<xref rid="bib28" ref-type="bibr">28</xref>,<xref rid="bib29" ref-type="bibr">29</xref>]. The transmission and infectivity related information of these viruses were summarized in <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>
. There are two seasonal flu viruses included, HCoVs and H3N2 IAV (HCoVs represents four CoVs that cause seasonal cold, HCoV229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1, for convenience in following discussion, they will be denoted as one CoV in this article.). They usually cause moderate clinical symptoms and spread globally [<xref rid="bib28" ref-type="bibr">28</xref>,<xref rid="bib30" ref-type="bibr">30</xref>]. The rest of six viruses either show high pathogenicity or are highly transmissible, which could cause much danger for human society. These viruses are called here as HPHTs, which stands for high pathogenicity or highly transmissible viruses. Of the HPHTs, the spread of SARS-CoV-2 is accelerated due to its ability to transmit through airborne droplets during the incubation period [<xref rid="bib31" ref-type="bibr">31</xref>]. That it may also transmit between human and animals becomes another challenge in the control of the pandemic [<xref rid="bib31" ref-type="bibr">31</xref>]. Another two viruses, MERS-CoV and SARS-CoV, reported in 2012 and 2003 respectively, caused mortalities of 35% and 9% in patients respectively. Their transmission mostly started after the patients started showing clinical symptoms [<xref rid="bib15" ref-type="bibr">15</xref>,<xref rid="bib32" ref-type="bibr">32</xref>]. Therefore, they could not travel in humans too long before being discovered and controlled. All ages of people were susceptible to these 3 CoVs, but senior people were more likely to be infected with SARS-CoV-2 and develop more severe clinical symptoms, while mostly younger people were infected with SARS-CoV [<xref rid="bib33" ref-type="bibr">33</xref>,<xref rid="bib34" ref-type="bibr">34</xref>].<table-wrap position="float" id="tbl1"><label>Table&#x000a0;1</label><caption><p>A summary of transmission of CoVs and IAVs.</p></caption><alt-text id="alttext0015">Table&#x000a0;1</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Viruses</th><th rowspan="2">First circulated</th><th colspan="3">Transmitted by contact via<hr/></th><th rowspan="2">Susceptible age</th><th rowspan="2">Infected people</th><th rowspan="2">Infected countries</th><th rowspan="2">Mortality</th><th rowspan="2">Intermediate host</th><th rowspan="2">References</th></tr><tr><th>Human to human</th><th>Human to animal</th><th>Airborne droplets</th></tr></thead><tbody><tr><td colspan="11"><bold>Highly pathogenic or highly transmissible</bold></td></tr><tr><td>SARS-CoV-2</td><td>2019</td><td>Yes</td><td>NA<xref rid="tbl1fnb" ref-type="table-fn">b</xref></td><td>Yes</td><td>Most were senior</td><td>Above 2 million by May 30 of 2020</td><td>Global</td><td>About 7% by May 12 of 2020</td><td>NA</td><td>[<xref rid="bib31" ref-type="bibr">31</xref>,<xref rid="bib33" ref-type="bibr">33</xref>,<xref rid="bib44" ref-type="bibr">44</xref>,<xref rid="bib45" ref-type="bibr">45</xref>]</td></tr><tr><td>MERS-CoV</td><td>2012</td><td>Rarely</td><td>Yes</td><td>Yes</td><td>All ages</td><td>2468 by November of 2019</td><td>27</td><td>About 35%</td><td>Dromedary camel, bat</td><td>[<xref rid="bib15" ref-type="bibr">15</xref>,<xref rid="bib32" ref-type="bibr">32</xref>,<xref rid="bib34" ref-type="bibr">34</xref>]</td></tr><tr><td>SARS-CoV</td><td>2003</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Most were younger</td><td>8447</td><td>32</td><td>9%</td><td>Palm civet, bat</td><td>[<xref rid="bib15" ref-type="bibr">15</xref>,<xref rid="bib33" ref-type="bibr">33</xref>,<xref rid="bib46" ref-type="bibr">46</xref>]</td></tr><tr><td>H7N9 IAV</td><td>2013</td><td>Rarely</td><td>Yes</td><td>Yes</td><td>Most were senior</td><td>1568 by December of 2019</td><td>Mainly in china</td><td>37%</td><td>Avian</td><td>[<xref rid="bib42" ref-type="bibr">42</xref>,<xref rid="bib47" ref-type="bibr">47</xref>]<break/>[<xref rid="bib48" ref-type="bibr">48</xref>]</td></tr><tr><td>H1N1pdm09</td><td>2009</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Most were younger</td><td>Above 200 million</td><td>Global</td><td>0.001%&#x02013;0.007%</td><td>Swine</td><td>[<xref rid="bib36" ref-type="bibr">36</xref>,<xref rid="bib49" ref-type="bibr">49</xref>]<break/>[<xref rid="bib50" ref-type="bibr">50</xref>]</td></tr><tr><td>H5N1 IAV</td><td>1997</td><td>Rarely</td><td>Yes</td><td>Yes</td><td>Most were younger</td><td>861 (2003&#x02013;2020)</td><td>17 (2003&#x02013;2020)</td><td>53%</td><td>Avian</td><td>[<xref rid="bib41" ref-type="bibr">41</xref>,<xref rid="bib49" ref-type="bibr">49</xref>]<break/>[<xref rid="bib51" ref-type="bibr">51</xref>]</td></tr><tr><td colspan="11"><bold>Seasonal</bold></td></tr><tr><td>HCoVs<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td>1966</td><td>Yes</td><td>Yes</td><td>Yes</td><td>All ages</td><td>up to 20% of cold cases</td><td>Global</td><td>NA</td><td>Bat, mice, cattle, palm civet</td><td>[<xref rid="bib14" ref-type="bibr">14</xref>,<xref rid="bib28" ref-type="bibr">28</xref>,<xref rid="bib52" ref-type="bibr">[52]</xref>, <xref rid="bib53" ref-type="bibr">[53]</xref>, <xref rid="bib54" ref-type="bibr">[54]</xref>]</td></tr><tr><td>H3N2 IAV</td><td>1968</td><td>Yes</td><td>Yes</td><td>NA</td><td>Most were senior</td><td>NA</td><td>Global</td><td>NA</td><td>Swine</td><td>[<xref rid="bib29" ref-type="bibr">29</xref>,<xref rid="bib30" ref-type="bibr">30</xref>,<xref rid="bib49" ref-type="bibr">49</xref>,<xref rid="bib54" ref-type="bibr">54</xref>]</td></tr></tbody></table><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntpara0015">HCoVs represents the four CoVs which caused common cold, HCoV229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnb"><label>b</label><p id="ntpara0020">NA, data unavailable.</p></fn></table-wrap-foot></table-wrap></p><p id="p0150">Some subtypes of IAVs also resulted in pandemic and caused large number of death tolls. Besides the well documented Spanish flu in 1918, H1N1pdm09 virus spread to 214 countries one year after it appeared in USA in 2009 [<xref rid="bib35" ref-type="bibr">35</xref>]. It was noticed that the virus caused more deaths in people who are younger than 65 [<xref rid="bib36" ref-type="bibr">36</xref>]. Some scientists deduced that the senior people may carry the immune memories from those induced by 1918H1N1-like flu viruses in their early years, which cross protected them from the H1N1pdm09 virus attack [<xref rid="bib37" ref-type="bibr">37</xref>]. However, the fact is that the 1918H1N1 virus also caused more deaths in younger people [<xref rid="bib38" ref-type="bibr">38</xref>]. H7N9 and H5N1 viruses were limited in transmission due to the similar reason mentioned above with MERS-CoV and SARS-CoV. However, the mortality of H7N9 is as high as 37%, and H5N1 is 53% [<xref rid="bib39" ref-type="bibr">39</xref>,<xref rid="bib40" ref-type="bibr">40</xref>]. Nevertheless, the high pathogenicity and high mortality make them easier to be identified and controlled at the beginning of the break. Although H7N9 and H5N1 viruses transmitted in humans ineffectively, their geographic expansion and genetic recombination still suggested the potential of forming the next pandemic [<xref rid="bib41" ref-type="bibr">41</xref>,<xref rid="bib42" ref-type="bibr">42</xref>].</p><p id="p0155">As listed in <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>, people are easily infected with CoVs or IAVs through direct contact and airborne droplets [<xref rid="bib43" ref-type="bibr">43</xref>]. Since most of these viruses are of animal origin or use animals as intermediate hosts [<xref rid="bib29" ref-type="bibr">29</xref>,<xref rid="bib31" ref-type="bibr">31</xref>], it is necessary to keep a safe distance between humans and wild animals, as well as maintaining ecological balance in the world to prevent the breaking of epidemics in future.</p></sec><sec id="sec3"><label>3</label><title>Clinical symptoms and diagnosis</title><p id="p0160">The major clinical symptoms are summarized in <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>
. With the overview of the 8 viruses, the average incubation periods of the three HPCoVs are about 5 days or more, which are a little longer than other viruses. At the early stage of disease onset, the cases with the infection of different viruses mostly developed the same clinical symptoms -- cough and fever. However other clinical symptoms were various, such as myalgia which was common in HPCoVs, H1N1pdm09, and H3N2 IAV infection. Dyspnea was present in HPHTs infection, but not common in seasonal virus infections. Diarrhea was usually observed in patients with MERS and SARS, but not common in the other virus infections.<table-wrap position="float" id="tbl2"><label>Table&#x000a0;2</label><caption><p>Major clinical symptoms of the CoVs and IAVs.</p></caption><alt-text id="alttext0020">Table&#x000a0;2</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Viruses</th><th colspan="6">Highly pathogenic or highly transmissible<hr/></th><th colspan="2">Seasonal<hr/></th></tr><tr><th>SARS-CoV-2</th><th>MERS-CoV</th><th>SARS-CoV</th><th>H7N9 IAV</th><th>H1N1pdm09</th><th>H5N1 IAV</th><th>HCoVs</th><th>H3N2 IAV</th></tr></thead><tbody><tr><td>Incubation period (day)</td><td>Average 5.2</td><td>Average 5.2</td><td>Average 4.6</td><td>Average 5</td><td>2 to 7</td><td>2 to 5</td><td>2 to 5</td><td>NA<xref rid="tbl2fnf" ref-type="table-fn">f</xref></td></tr><tr><td colspan="9"><bold>Early stage of onset</bold></td></tr><tr><td>Sore throat</td><td>&#x02013;<xref rid="tbl2fnc" ref-type="table-fn">c</xref></td><td>&#x000b1;</td><td>&#x000b1;</td><td>&#x02013;</td><td>&#x0ff0b;</td><td>&#x000b1;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td></tr><tr><td>Cough</td><td>&#x0ff0b;<xref rid="tbl2fnd" ref-type="table-fn">d</xref></td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td></tr><tr><td>Fever</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td></tr><tr><td>Myalgia</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x000b1;</td><td>&#x0ff0b;</td><td>&#x000b1;</td><td>&#x000b1;</td><td>&#x0ff0b;</td></tr><tr><td>Dyspnea</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x000b1;</td><td>&#x02013;</td></tr><tr><td>Nausea and/or vomiting</td><td>&#x000b1;<xref rid="tbl2fne" ref-type="table-fn">e</xref></td><td>20%&#x02013;35%</td><td>20%</td><td>About 13%</td><td>25%</td><td>&#x000b1;</td><td>&#x02013;</td><td>&#x000b1;</td></tr><tr><td>Diarrhea</td><td>&#x000b1;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>About 13%</td><td>25%</td><td>&#x000b1;</td><td>&#x000b1;</td><td>&#x000b1;</td></tr><tr><td colspan="9"><bold>Later stage of onset</bold></td></tr><tr><td>Bilateral pneumonia</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x000b1;</td><td>NA</td></tr><tr><td>Ground glass pneumonia</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x000b1;</td><td>&#x02013;</td><td>&#x02013;</td><td>NA</td></tr><tr><td>Hepatic injury</td><td>&#x000b1;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x000b1;</td><td>&#x0ff0b;</td><td>&#x02013;</td><td>NA</td></tr><tr><td>Kidney injury</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x02013;</td><td>&#x0ff0b;</td></tr><tr><td>Heart failure</td><td>&#x0ff0b;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x000b1;</td><td>&#x000b1;</td><td>&#x0ff0b;</td><td>&#x02013;</td><td>NA</td></tr><tr><td>ARDS<xref rid="tbl2fna" ref-type="table-fn">a</xref></td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x02013;</td><td>NA</td></tr><tr><td>LDH increase<xref rid="tbl2fnb" ref-type="table-fn">b</xref></td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x02013;</td><td>NA</td></tr><tr><td>Lymphocytopenia</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x02013;</td><td>&#x0ff0b;</td></tr><tr><td>Critical patient ratio</td><td>10.0&#x02013;30.6% ICU</td><td>50% ICU</td><td>25% ICU</td><td>&#x0003e;70%</td><td>25%</td><td>63%</td><td>3.17%</td><td>0.40%</td></tr><tr><td>Onset to critical (day)</td><td>10</td><td>5</td><td>7</td><td>7</td><td>3 to 5</td><td>2</td><td>NA</td><td>NA</td></tr><tr><td>References</td><td>[<xref rid="bib55" ref-type="bibr">[55]</xref>, <xref rid="bib56" ref-type="bibr">[56]</xref>, <xref rid="bib57" ref-type="bibr">[57]</xref>, <xref rid="bib58" ref-type="bibr">[58]</xref>]</td><td>[<xref rid="bib34" ref-type="bibr">34</xref>,<xref rid="bib59" ref-type="bibr">[59]</xref>, <xref rid="bib60" ref-type="bibr">[60]</xref>, <xref rid="bib61" ref-type="bibr">[61]</xref>]</td><td>[<xref rid="bib52" ref-type="bibr">52</xref>,<xref rid="bib62" ref-type="bibr">[62]</xref>, <xref rid="bib63" ref-type="bibr">[63]</xref>, <xref rid="bib64" ref-type="bibr">[64]</xref>, <xref rid="bib65" ref-type="bibr">[65]</xref>]</td><td>[<xref rid="bib66" ref-type="bibr">[66]</xref>, <xref rid="bib67" ref-type="bibr">[67]</xref>, <xref rid="bib68" ref-type="bibr">[68]</xref>, <xref rid="bib69" ref-type="bibr">[69]</xref>]</td><td>[<xref rid="bib70" ref-type="bibr">[70]</xref>, <xref rid="bib71" ref-type="bibr">[71]</xref>, <xref rid="bib72" ref-type="bibr">[72]</xref>, <xref rid="bib73" ref-type="bibr">[73]</xref>, <xref rid="bib74" ref-type="bibr">[74]</xref>]</td><td>[<xref rid="bib75" ref-type="bibr">[75]</xref>, <xref rid="bib76" ref-type="bibr">[76]</xref>, <xref rid="bib77" ref-type="bibr">[77]</xref>]</td><td>[<xref rid="bib78" ref-type="bibr">[78]</xref>, <xref rid="bib79" ref-type="bibr">[79]</xref>, <xref rid="bib80" ref-type="bibr">[80]</xref>]</td><td>[<xref rid="bib81" ref-type="bibr">[81]</xref>, <xref rid="bib82" ref-type="bibr">[82]</xref>, <xref rid="bib83" ref-type="bibr">[83]</xref>, <xref rid="bib84" ref-type="bibr">[84]</xref>]</td></tr></tbody></table><table-wrap-foot><fn id="tbl2fna"><label>a</label><p id="ntpara0025">ARDS, Acute respiratory distress syndrome.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnb"><label>b</label><p id="ntpara0030">LDH, Lactate dehydrogenase.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnc"><label>c</label><p id="ntpara0035">&#x0201c;&#x02013;&#x0201d;, uncommon or none.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnd"><label>d</label><p id="ntpara0040">&#x0201c;&#x0ff0b;&#x0201d;, common.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fne"><label>e</label><p id="ntpara0045">&#x0201c;&#x000b1;&#x0201d;, some cases.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnf"><label>f</label><p id="ntpara0050">NA, data unavailable.</p></fn></table-wrap-foot></table-wrap></p><p id="p0165">At the late stage of disease onset, compared with the seasonal viruses, all of the HPHTs can result in similar severe clinical symptoms, such as bilateral pneumonia, kidney damage, acute respiratory distress syndrome (ARDS), lactate dehydrogenase, and lymphocytopenia. In addition, three HPCoVs and H7N9 IAV infection usually showed ground glass pneumonia. MERS-CoV, SARS-CoV, H7N9 IAV, and H5N1 IAV caused more hepatic injury. SARS-CoV-2 and H5N1 IAV meanwhile caused more heart failure. The critical patient ratio of the HPHTs infection can be 10%&#x02013;70% after 2&#x02013;10 days of the disease development.</p><p id="p0170">To detect the causative viruses, similar measures were applied for CoVs and IAVs. The specimen can be swabs, blood, or trachea extracts. Then the viral RNAs can be directly identified by reverse transcription polymerase chain reaction (RT-PCR) based methods, and the virus specific antibodies can be detected with enzyme-linked immunosorbent assay (ELISA) or related serological methods. More detailed information has been summarized in the previous publication [<xref rid="bib13" ref-type="bibr">13</xref>]. In order to deal with the simultaneous transmission of IAVs and CoVs, especially the new coronavirus, it is necessary to develop rapid and simple differential diagnosis technologies and methods for identification of IAVs and CoVs.</p></sec><sec id="sec4"><label>4</label><title>Pathological change</title><p id="p0175">Both CoVs and IAVs can cause ARDS and lead to multiple organ failure and death. The published pathological data that were collected from autopsy, lung biopsies and chest computed tomography (CT) scan are summarized in <xref rid="tbl3" ref-type="table">Table&#x000a0;3</xref>
. For patients with HPHTs infection, the general manifestations of the lung pathological change were inflammatory exudation or acute diffuse alveolar damage (DAD), with hyaline membrane formation, fibrin mucoid exudation, interstitial and alveolar edema, inflammatory interstitial infiltration and vascular congestion, epithelial cell proliferation, and pulmonary consolidation. However, there is no fibrin exudate found in the lungs of MERS patients, which may be related to the different stage of the disease progression. Almost all of the virus infections caused bronchioles injury except COVID-19 and H7N9 IAV [<xref rid="bib85" ref-type="bibr">85</xref>,<xref rid="bib86" ref-type="bibr">86</xref>], presented as the aggregation of fibrin in the bronchial intracavitary, the loss of cilia, the exfoliation of bronchioles epithelium, etc. It was reported that HCoVs were found to be associated with bronchiolitis in immunocompromised people, the elderly and young children, but showed light disease in the lungs.<table-wrap position="float" id="tbl3"><label>Table&#x000a0;3</label><caption><p>The pathological changes of the patients after infection.</p></caption><alt-text id="alttext0025">Table&#x000a0;3</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Viruses</th><th colspan="6">Highly pathogenic or highly transmissible<hr/></th><th colspan="2">Seasonal<hr/></th></tr><tr><th>SARS-CoV-2</th><th>MERS-CoV</th><th>SARS-CoV</th><th>H7N9 IAV</th><th>H1N1pdm09</th><th>H5N1 IAV</th><th>HCoVs</th><th>H3N2 IAV</th></tr></thead><tbody><tr><td>Diffuse alveolar damage</td><td>&#x0ff0b;<xref rid="tbl3fna" ref-type="table-fn">a</xref></td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x02013;<xref rid="tbl3fnb" ref-type="table-fn">b</xref></td><td>NA<xref rid="tbl3fnc" ref-type="table-fn">c</xref></td></tr><tr><td>Hyaline membrane</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x02013;</td><td>&#x0ff0b;</td></tr><tr><td>The pulmonary interstitial edema and lymphocytic infiltration</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x02013;</td><td>&#x0ff0b;</td></tr><tr><td>Fibromyxoid exudation</td><td>&#x0ff0b;</td><td>&#x02013;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x02013;</td><td>&#x0ff0b;</td></tr><tr><td>Pulmonary consolidation</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x02013;</td><td>NA</td></tr><tr><td>Bronchiolitis</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x02013;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td><td>&#x0ff0b;</td></tr><tr><td>References</td><td>[<xref rid="bib87" ref-type="bibr">[87]</xref>, <xref rid="bib88" ref-type="bibr">[88]</xref>, <xref rid="bib89" ref-type="bibr">[89]</xref>]</td><td>[<xref rid="bib61" ref-type="bibr">61</xref>,<xref rid="bib90" ref-type="bibr">90</xref>]</td><td>[<xref rid="bib91" ref-type="bibr">[91]</xref>, <xref rid="bib92" ref-type="bibr">[92]</xref>, <xref rid="bib93" ref-type="bibr">[93]</xref>]</td><td>[<xref rid="bib94" ref-type="bibr">94</xref>,<xref rid="bib95" ref-type="bibr">95</xref>]</td><td>[<xref rid="bib96" ref-type="bibr">[96]</xref>, <xref rid="bib97" ref-type="bibr">[97]</xref>, <xref rid="bib98" ref-type="bibr">[98]</xref>]</td><td>[<xref rid="bib99" ref-type="bibr">[99]</xref>, <xref rid="bib100" ref-type="bibr">[100]</xref>, <xref rid="bib101" ref-type="bibr">[101]</xref>, <xref rid="bib102" ref-type="bibr">[102]</xref>]</td><td>[<xref rid="bib103" ref-type="bibr">[103]</xref>, <xref rid="bib104" ref-type="bibr">[104]</xref>, <xref rid="bib105" ref-type="bibr">[105]</xref>, <xref rid="bib106" ref-type="bibr">[106]</xref>]</td><td>[<xref rid="bib107" ref-type="bibr">107</xref>]</td></tr></tbody></table><table-wrap-foot><fn id="tbl3fna"><label>a</label><p id="ntpara0055">&#x0201c;&#x0ff0b;&#x0201d;, common.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnb"><label>b</label><p id="ntpara0060">&#x0201c;&#x02212;&#x0201d;, uncommon or none.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnc"><label>c</label><p id="ntpara0065">NA, data not available.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec5"><label>5</label><title>Treatment</title><p id="p0180">The RNA virus inhibitors were designed to target the different steps of virus replication cycle. Some of them inhibit virus entry or release, some interfere gene synthesis, and some inhibit virus protease, or some modulate innate immune response, like interferons etc. However, there are no specific drugs for treatment of CoVs infection. Most often used for treatment of SARS and MERS are ribavirin and lopinavir/ritonavir. Ribavirin is similar to guanosine and inosine and interfere viral RNA replication, which is more frequently used in combination with interferons to treat chronic hepatitis C infection [<xref rid="bib108" ref-type="bibr">108</xref>]. Lopinavir and ritonavir are two protease inhibitors previously approved for HIV treatment, which usually used together and ritonavir as CYP3A4 inhibitor to enhance the activity of lopinavir [<xref rid="bib109" ref-type="bibr">109</xref>].</p><p id="p0185">The suitable medications for COVID-19 are still under search. So far, one of the most promising drugs is remdesivir (GS-5734), produced by Gilead Science, a nucleoside analog that mimics adenosine for previously treatment of the Ebola virus infection [<xref rid="bib110" ref-type="bibr">110</xref>]. Health authorities in China have initiated clinical trials at multiple places in Hubei province to evaluate the safety and efficacy of remdesivir on patients. However, under the pandemic emergencies, the patients who recovered from critical situation usually took multiple medications rather than remdesivir, which made assessment of the data from clinical trials somewhat complicated [<xref rid="bib111" ref-type="bibr">111</xref>]. Besides of China, Gilead Science started phase III trial. National Institute of Allergy and Infectious Diseases (NIAID) in the US are conducting phase II trial. The French National Institute of Health and Medical Research (INSERM) also evaluated the effect of remdesivir and other treatment on COVID-19 patients [<xref rid="bib112" ref-type="bibr">112</xref>].</p><p id="p0190">Another promising drug is chloroquine or its analog, hydroxychloroquine. It was reported that these two drugs may inhibit viral entry by affecting PH dependent endocytosis, and they may also affect viral glycosylation by inhibiting glycosyl-transferases [<xref rid="bib113" ref-type="bibr">113</xref>]. They were approved to treat or prevent malaria, as well as rheumatoid arthritis, or systemic lupus erythematosus etc. Moreover, hydroxychloroquine showed fewer side effects than chloroquine [<xref rid="bib114" ref-type="bibr">114</xref>]. Several clinical studies on hydroxychloroquine and chloroquine provided fairly satisfying results, better trial designing would be needed to further confirm the therapeutic effectiveness [<xref rid="bib115" ref-type="bibr">115</xref>]. Besides of these medications, lopinavir/ritonavir, interferons, as well as the Chinese medicine formulate were also recommended by China for treatment of COVID-19 [<xref rid="bib116" ref-type="bibr">116</xref>].</p><p id="p0195">Currently, for clinical treatment of influenza infection, there are only three classes of FDA (Food and Drug Administration)-approved antiviral drugs available, including M2 ion channel inhibitors (amantadine and rimantadine), neuraminidase inhibitors (oseltamivir, zanamivir, peramivir and laninamivir), and the most recently RNA polymerase inhibitors (balxavirmarboxil) [<xref rid="bib117" ref-type="bibr">117</xref>].</p><p id="p0200">Amantadine and rimantadine can prevent the virus from shelling in the cytoplasm, thus inhibiting the transmission of virus offspring [<xref rid="bib118" ref-type="bibr">118</xref>]. Although developed for many years, it has been reported frequently that they are ineffective in clinical treatment due to drug resistance of almost all currently circulating IAVs [<xref rid="bib119" ref-type="bibr">119</xref>]. Furthermore, they have a relatively large side effect on the human central nervous system, thus are no longer recommended by WHO as the first choice of anti-influenza drugs for the treatment or prophylaxis of influenza [<xref rid="bib118" ref-type="bibr">118</xref>].</p><p id="p0205">Until now, the neuraminidase inhibitors (NAIs) are still the most ideal reagents for clinical treatment [<xref rid="bib120" ref-type="bibr">120</xref>]. NAIs can prevent the hydrolytic activity of neuraminidase when the mature virus leaves the cell after budding, therefore stopping the virus from infecting healthy cells [<xref rid="bib121" ref-type="bibr">121</xref>]. However, with heavy use in clinic, widespread oseltamivir-resistant H1N1 H275Y mutants have been identified [<xref rid="bib122" ref-type="bibr">122</xref>]. According to a study carried out between 2008 and 2012 by WHO, oseltamivir resistance was found to be 2.9% (16/656 patients) [<xref rid="bib123" ref-type="bibr">123</xref>], raising the alert that whether we can deal with influenza viruses once they break through the last line of defense? It has been found that probenecid can prevent the renal secretion of the parent compound of oseltamivir and significantly increase the blood concentration of oseltamivir [<xref rid="bib124" ref-type="bibr">124</xref>]. Therefore the combination of oseltamivir and probenecid may be an important treatment option for severe patients.</p><p id="p0210">Balxavir marboxil, with a brand name of Xofloza, can target to viral polymerase acidic protein (PA), block its endonuclease function, leading to the inhibition of virus mRNA transcription and effectively prevent influenza A virus infection [<xref rid="bib125" ref-type="bibr">[125]</xref>, <xref rid="bib126" ref-type="bibr">[126]</xref>, <xref rid="bib127" ref-type="bibr">[127]</xref>]. The antiviral spectrum of Xofloza includes seasonal influenza strains and influenza strains resistant to oseltamivir, significantly reducing the viral load compared with oseltamivir [<xref rid="bib128" ref-type="bibr">128</xref>]. T-705 is a new type of RNA polymerase inhibitor which can inhibit a wide range of viruses by directly entering into the viral RNA chain or by binding directly to the viral RNA polymerase domain to block viral RNA chain replication and transcription [<xref rid="bib129" ref-type="bibr">129</xref>,<xref rid="bib130" ref-type="bibr">130</xref>]. It has been approved for listing in Japan [<xref rid="bib131" ref-type="bibr">131</xref>,<xref rid="bib132" ref-type="bibr">132</xref>].</p><p id="p0215">With this in mind, it is quite urgent to develop novel anti-influenza drugs with higher antiviral potency and resistance barrier. Hemagglutinin glycoprotein, located on the surface of influenza virions [<xref rid="bib133" ref-type="bibr">133</xref>], plays a critical role in virus attachment and membrane fusion. Accompanied with HA structure characteristics elucidated, HA inhibitors appear to be one of the most promising candidates [<xref rid="bib134" ref-type="bibr">[134]</xref>, <xref rid="bib135" ref-type="bibr">[135]</xref>, <xref rid="bib136" ref-type="bibr">[136]</xref>, <xref rid="bib137" ref-type="bibr">[137]</xref>]. With high efficacy and broad antiviral activity, some inhibitors targeting HA such as DAS181 and arbidol are currently in clinical development stage or partly approved for influenza virus infection [<xref rid="bib138" ref-type="bibr">[138]</xref>, <xref rid="bib139" ref-type="bibr">[139]</xref>, <xref rid="bib140" ref-type="bibr">[140]</xref>]. Considering the antigen drift and shift of IAVs, the conserved regions on HA, such as the HA1 receptor binding sites (RBS) and the HA2 stem domain, are more attractive for new drug design [<xref rid="bib141" ref-type="bibr">[141]</xref>, <xref rid="bib142" ref-type="bibr">[142]</xref>, <xref rid="bib143" ref-type="bibr">[143]</xref>]. A number of broad-spectrum neutralizing antibodies targeting above the two domains have been identified. For example, CR9114 exerts a broader antiviral effect against both influenza A and B viruses in mice by binding to HA stem domain, which may be useful for the treatment of severe influenza disease [<xref rid="bib144" ref-type="bibr">144</xref>].</p></sec><sec id="sec6"><label>6</label><title>Prevention</title><p id="p0220">There are many types of vaccines that have been used or are under investigation for human viral disease, such as live attenuated virus vaccine, inactivated whole virus vaccine, subunit or recombinant vaccine, DNA plasmids based vaccine, and mRNA based vaccine. However, there are no available vaccines for prevention of CoV infection. More than 10 years of research on the development of vaccines against MERS-CoV and SARS-CoV indicated that S protein has the ability to induce neutralizing antibodies to stop virus infection [<xref rid="bib145" ref-type="bibr">145</xref>,<xref rid="bib146" ref-type="bibr">146</xref>], which shines light on SARS-CoV-2 vaccine study.</p><p id="p0225">For development of SARS-CoV-2 vaccine, an intense global effort is currently underway [<xref rid="bib147" ref-type="bibr">147</xref>]. So far several vaccines candidates have moved into clinical trials in China. One of them moved into phase II trail on April 12, which was produced by the Institute of Bioengineering, Academy of Military Medicine (NCT04341389) [<xref rid="bib148" ref-type="bibr">148</xref>]. The research team led by Professor Chen took the modified replication defective adenovirus as the vector, carried the S gene of the new CoV, to stimulate immune memory of S protein in humans. Their phase I trial was finished on March 27. In total 108 volunteers have completed the centralized medical observation without showing side effects (NCT04313127). In addition, LV-SMENP-DC, a dendritic cells vaccine, transduced with a lentivirus vector expression of several minigenes of SARS-CoV-2 and immunomodulatory genes, was developed by Shenzhen Geno-Immune Medical Institute (SGIMI) in China and used for injection of people along with activated virus antigen-specific cytotoxic T cells (NCT04276896). SGIMI also developed a second one using artificial antigen presenting cells (aAPCs) modified with lentivirus vector carrying similar genes with LV-SMENP-DC (NCT04299724). Two inactivated vaccines were approved for clinical trial as well, developed by the China National Pharmaceutical Group (Sinopharm) and Sinovac Research and Development Co., Ltd (NCT04352608) [<xref rid="bib147" ref-type="bibr">147</xref>,<xref rid="bib149" ref-type="bibr">[149]</xref>, <xref rid="bib150" ref-type="bibr">[150]</xref>, <xref rid="bib151" ref-type="bibr">[151]</xref>, <xref rid="bib152" ref-type="bibr">[152]</xref>].</p><p id="p0230">In addition to COVID-19 vaccine clinical trials in China, there are many SARS-CoV-2 vaccine clinical trials underway worldwide [<xref rid="bib153" ref-type="bibr">153</xref>], such as a mRNA vaccine, mRNA-1273, produced by Moderna, Inc. in US (NCT04283461); a DNA vaccine, INO-4800 by Inovio, Inc. in US (NCT04336410); Bifidobacterium probiotic carrying S protein gene by Symvivo in Canada (NCT04334980); adenovirus vaccine vector carrying S protein in UK (NCT04324606), etc. Whereas SARS-CoV-2 only started emerging in the human population, S protein, a major direct receptor interaction protein, and other viral proteins may continue modifying themselves to better adapt to humans [<xref rid="bib154" ref-type="bibr">154</xref>]. Gene modification will bring more challenges into vaccine designing and development, especially the mutation in S protein which has been picked up by most of the vaccines candidates mentioned above.</p><p id="p0235">Since the first H1N1 IAV vaccine was generated for prevention of the Spanish flu in 1938 by Jonas Salk and Thomas Francis [<xref rid="bib155" ref-type="bibr">155</xref>,<xref rid="bib156" ref-type="bibr">156</xref>], influenza vaccines have been improved dramatically. There are many types vaccines approved in US with trade names such as FluLaval, Fluarix, Agriflu, and Flublok. A live attenuated vaccine with the name of FluMist was approved by the Food and Drug Administration in US in 2003, and which is delivered through nasal spray [<xref rid="bib157" ref-type="bibr">157</xref>]. To decrease side effects, animal and insect cells were also approved to replace chicken embryos for growth of vaccine strain [<xref rid="bib158" ref-type="bibr">158</xref>]. To provide protection from most seasonal virus attacks using one shot, multiple dominant viruses were included into one vaccine, such as those containing 3 or 4 different circulating strains and called trivalent or quadrivalent vaccines [<xref rid="bib158" ref-type="bibr">158</xref>,<xref rid="bib159" ref-type="bibr">159</xref>]. Before a universal vaccine was successfully developed, it is necessary to switch vaccines strains year by year as the prevalent influenza viruses mutate their genes or change their subtypes very frequently to escape from the immune recognition [<xref rid="bib24" ref-type="bibr">24</xref>,<xref rid="bib29" ref-type="bibr">29</xref>].</p><p id="p0240">Up to now, available commercial vaccines against the IAVs those listed in this article are H1N1, H5N1 and H3N2 IAV vaccines, but not H7N9 flu vaccine. For example, a trivalent inactivated vaccine, TIV, produced by Seqirus Inc., usually has H1N1, H3N2 and B subtype viruses. FluMist, produced by Medimmune, Inc, is also used for H1N1 flu vaccine [<xref rid="bib158" ref-type="bibr">158</xref>]. For H5N1 IAV, several inactivated vaccines are approved for human use, such as Audenz produced by Seqirus Inc [<xref rid="bib158" ref-type="bibr">158</xref>], Prepandrix produced by GlaxoSmithKline Biologicals S.A [<xref rid="bib160" ref-type="bibr">160</xref>]. H3N2 virus is usually a seasonal flu subtype in the last 30 years, of which the vaccine has been recommended for injection according to flu surveillance [<xref rid="bib29" ref-type="bibr">29</xref>].</p></sec><sec id="sec7"><label>7</label><title>Summary</title><p id="p0245">Human CoVs and IAVs share many characteristics, especially in HPHTs. Most of them infect the respiratory tract through direct contact and airway droplets and cause similar clinical symptoms like fever, cough, and sore throat. In contrast, MERS-CoV, H7N9 and H5N1 viruses rarely transmit between humans. SARS-CoV, H1N1pdm09, and H5N1 viruses easily infect younger people. Severe patients usually infected with HPHTs develop bilateral pneumonia, ARDS, respiratory failure, and even death. CT and autopsy showed that the main pulmonary pathological manifestations were DAD, hyaline membrane formation, alveolar and interstitial edema, fibromyxoid exudation, etc. At present, there are no specific and effective drugs or vaccines for the treatment and prevention of CoVs. However, thanks to clinicians&#x02019; and scientists&#x02019; efforts worldwide, some promising progress has been made in the treatment of the diseases. Although there are some drugs and vaccines for the treatment and prevention of IAVs, it is still necessary to further research and develop more effective methods of treatment and prevention to better control the influenza epidemic.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="p0250">The authors declare that they have no conflicts of interest.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>X.</given-names></name><name><surname>Ojcius</surname><given-names>D.M.</given-names></name><name><surname>Gao</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Pan</surname><given-names>C.</given-names></name><name><surname>Pan</surname><given-names>C.</given-names></name></person-group><article-title>Lessons learned from the 2019-nCoV epidemic on prevention of future infectious diseases</article-title><source>Microbes Infect</source><volume>22</volume><year>2020</year><fpage>86</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">32088333</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="other" id="sref2"><ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019" id="intref0010">https://www.who.int/emergencies/diseases/novel-coronavirus-2019</ext-link></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Mahase</surname><given-names>E.</given-names></name></person-group><article-title>Covid-19: outbreak could last until spring 2021 and see 7.9 million hospitalised in the UK</article-title><source>BMJ</source><volume>368</volume><year>2020</year><fpage>m1071</fpage><pub-id pub-id-type="pmid">32179567</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Khodamoradi</surname><given-names>Z.</given-names></name><name><surname>Moghadami</surname><given-names>M.</given-names></name><name><surname>Lotfi</surname><given-names>M.</given-names></name></person-group><article-title>Co-infection of coronavirus disease 2019 and influenza A: a report from Iran</article-title><source>Arch Iran Med</source><volume>23</volume><year>2020</year><fpage>239</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">32271596</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Cai</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name></person-group><article-title>Co-infection with SARS-CoV-2 and influenza A virus in patient with pneumonia, China</article-title><source>Emerg Infect Dis</source><volume>26</volume><year>2020</year></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>Q.</given-names></name><name><surname>Lu</surname><given-names>P.</given-names></name><name><surname>Fan</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name></person-group><article-title>The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China</article-title><source>J&#x000a0;Med Virol</source><year>2020</year><pub-id pub-id-type="doi">10.1002/jmv.25781</pub-id><comment>[online ahead of print]</comment></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Maier</surname><given-names>H.J.</given-names></name><name><surname>Bickerton</surname><given-names>E.</given-names></name><name><surname>Britton</surname><given-names>P.</given-names></name></person-group><article-title>Preface. Coronaviruses</article-title><source>Methods Mol Biol</source><volume>1282</volume><year>2015</year><fpage>v</fpage><pub-id pub-id-type="pmid">25870870</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Hillyer</surname><given-names>C.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name></person-group><article-title>Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses</article-title><source>Trends Immunol</source><volume>41</volume><year>2020</year><fpage>355</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">32249063</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name></person-group><article-title>Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines</article-title><source>Virology</source><volume>334</volume><year>2005</year><fpage>74</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">15749124</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Lan</surname><given-names>Q.</given-names></name><name><surname>Feng</surname><given-names>S.</given-names></name></person-group><article-title>Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion</article-title><source>Cell Res</source><volume>30</volume><year>2020</year><fpage>343</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">32231345</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Xiao</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Niu</surname><given-names>J.</given-names></name><name><surname>Escalante</surname><given-names>C.R.</given-names></name></person-group><article-title>Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors</article-title><source>Lancet</source><volume>363</volume><year>2004</year><fpage>938</fpage><lpage>947</lpage><pub-id pub-id-type="pmid">15043961</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Ge</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>L.F.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name></person-group><article-title>Bat origin of human coronaviruses</article-title><source>Virol J</source><volume>12</volume><year>2015</year><fpage>221</fpage><pub-id pub-id-type="pmid">26689940</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>F.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Ojcius</surname><given-names>D.M.</given-names></name><name><surname>Pan</surname><given-names>C.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China</article-title><source>Microb Infect</source><volume>22</volume><year>2020</year><fpage>74</fpage><lpage>79</lpage></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>Y.</given-names></name><name><surname>Wunderink</surname><given-names>R.G.</given-names></name></person-group><article-title>MERS, SARS and other coronaviruses as causes of pneumonia</article-title><source>Respirology</source><volume>23</volume><year>2018</year><fpage>130</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">29052924</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yu</surname><given-names>P.</given-names></name><name><surname>Qu</surname><given-names>Y.</given-names></name></person-group><article-title>From SARS to MERS, thrusting coronaviruses into the spotlight</article-title><source>Viruses</source><year>2019</year><fpage>11</fpage></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Dadonaite</surname><given-names>B.</given-names></name><name><surname>Gilbertson</surname><given-names>B.</given-names></name><name><surname>Knight</surname><given-names>M.L.</given-names></name><name><surname>Trifkovic</surname><given-names>S.</given-names></name><name><surname>Rockman</surname><given-names>S.</given-names></name><name><surname>Laederach</surname><given-names>A.</given-names></name></person-group><article-title>The structure of the influenza A virus genome</article-title><source>Nat Microbiol</source><volume>4</volume><year>2019</year><fpage>1781</fpage><lpage>1789</lpage><pub-id pub-id-type="pmid">31332385</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Dou</surname><given-names>D.</given-names></name><name><surname>Revol</surname><given-names>R.</given-names></name><name><surname>Ostbye</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Daniels</surname><given-names>R.</given-names></name></person-group><article-title>Influenza A virus cell entry, replication, virion assembly and movement</article-title><source>Front Immunol</source><volume>9</volume><year>2018</year><fpage>1581</fpage><pub-id pub-id-type="pmid">30079062</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Kosik</surname><given-names>I.</given-names></name><name><surname>Yewdell</surname><given-names>J.W.</given-names></name></person-group><article-title>Influenza hemagglutinin and neuraminidase: yin(-)Yang proteins coevolving to thwart immunity</article-title><source>Viruses</source><volume>11</volume><year>2019</year></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N.</given-names></name><name><surname>Zheng</surname><given-names>B.J.</given-names></name><name><surname>Lu</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name></person-group><article-title>Advancements in the development of subunit influenza vaccines</article-title><source>Microb Infect</source><volume>17</volume><year>2015</year><fpage>123</fpage><lpage>134</lpage></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Lloren</surname><given-names>K.K.S.</given-names></name><name><surname>Kwon</surname><given-names>J.J.</given-names></name><name><surname>Choi</surname><given-names>W.S.</given-names></name><name><surname>Jeong</surname><given-names>J.H.</given-names></name><name><surname>Ahn</surname><given-names>S.J.</given-names></name><name><surname>Choi</surname><given-names>Y.K.</given-names></name></person-group><article-title>In&#x000a0;vitro and in&#x000a0;vivo characterization of novel neuraminidase substitutions in influenza A(H1N1)pdm09 virus identified using laninamivir-mediated in&#x000a0;vitro selection</article-title><source>J&#x000a0;Virol</source><volume>93</volume><year>2019</year></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Walz</surname><given-names>L.</given-names></name><name><surname>Kays</surname><given-names>S.K.</given-names></name><name><surname>Zimmer</surname><given-names>G.</given-names></name><name><surname>von Messling</surname><given-names>V.</given-names></name></person-group><article-title>Neuraminidase-inhibiting antibody titers correlate with protection from heterologous influenza virus strains of the same neuraminidase subtype</article-title><source>J&#x000a0;Virol</source><volume>92</volume><year>2018</year></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name></person-group><article-title>Antibodies against H1N1 influenza virus cross-react with alpha-cells of pancreatic islets</article-title><source>J&#x000a0;Diabetes Investig</source><volume>9</volume><year>2018</year><fpage>265</fpage><lpage>269</lpage></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Fu</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>Lu</surname><given-names>M.</given-names></name></person-group><article-title>Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity</article-title><source>Science</source><volume>367</volume><year>2020</year></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>C.</given-names></name><name><surname>Cheung</surname><given-names>B.</given-names></name><name><surname>Tan</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name></person-group><article-title>Genomic signature and mutation trend analysis of pandemic (H1N1) 2009 influenza A virus</article-title><source>PloS One</source><volume>5</volume><year>2010</year><fpage>e9549</fpage><pub-id pub-id-type="pmid">20221396</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>B.</given-names></name><name><surname>Pichon</surname><given-names>M.</given-names></name><name><surname>Valette</surname><given-names>M.</given-names></name><name><surname>Burfin</surname><given-names>G.</given-names></name><name><surname>Richard</surname><given-names>M.</given-names></name><name><surname>Lina</surname><given-names>B.</given-names></name></person-group><article-title>Whole genome sequencing of A(H3N2) influenza viruses reveals variants associated with severity during the 2016(-)2017 season</article-title><source>Viruses</source><year>2019</year><fpage>11</fpage></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Tharakaraman</surname><given-names>K.</given-names></name><name><surname>Raman</surname><given-names>R.</given-names></name><name><surname>Viswanathan</surname><given-names>K.</given-names></name><name><surname>Stebbins</surname><given-names>N.W.</given-names></name><name><surname>Jayaraman</surname><given-names>A.</given-names></name><name><surname>Krishnan</surname><given-names>A.</given-names></name></person-group><article-title>Structural determinants for naturally evolving H5N1 hemagglutinin to switch its receptor specificity</article-title><source>Cell</source><volume>153</volume><year>2013</year><fpage>1475</fpage><lpage>1485</lpage><pub-id pub-id-type="pmid">23746829</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Samji</surname><given-names>T.</given-names></name></person-group><article-title>Influenza A: understanding the viral life cycle</article-title><source>Yale J Biol Med</source><volume>82</volume><year>2009</year><fpage>153</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">20027280</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Gaunt</surname><given-names>E.R.</given-names></name><name><surname>Hardie</surname><given-names>A.</given-names></name><name><surname>Claas</surname><given-names>E.C.</given-names></name><name><surname>Simmonds</surname><given-names>P.</given-names></name><name><surname>Templeton</surname><given-names>K.E.</given-names></name></person-group><article-title>Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method</article-title><source>J&#x000a0;Clin Microbiol</source><volume>48</volume><year>2010</year><fpage>2940</fpage><lpage>2947</lpage><pub-id pub-id-type="pmid">20554810</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Liao</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>G.H.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>High genetic and antigenic similarity between a swine H3N2 influenza A virus and a prior human influenza vaccine virus: a possible immune pressure-driven cross-species transmission</article-title><source>Biochem Biophys Res Commun</source><volume>385</volume><year>2009</year><fpage>402</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">19463787</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>J.D.</given-names></name><name><surname>Ross</surname><given-names>T.M.</given-names></name></person-group><article-title>H3N2 influenza viruses in humans: viral mechanisms, evolution, and evaluation</article-title><source>Hum Vaccines Immunother</source><volume>14</volume><year>2018</year><fpage>1840</fpage><lpage>1847</lpage></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Ning</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Gali</surname><given-names>N.K.</given-names></name></person-group><article-title>Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals</article-title><source>Nature</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41586-020-2271-3</pub-id><comment>[online ahead of print]</comment></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Baharoon</surname><given-names>S.</given-names></name><name><surname>Memish</surname><given-names>Z.A.</given-names></name></person-group><article-title>MERS-CoV as an emerging respiratory illness: a review of prevention methods</article-title><source>Trav Med Infect Dis</source><year>2019</year><fpage>101520</fpage></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Q.</given-names></name><name><surname>Lin</surname><given-names>Q.</given-names></name><name><surname>Jin</surname><given-names>S.</given-names></name><name><surname>You</surname><given-names>L.</given-names></name></person-group><article-title>Coronavirus 2019-nCoV: a brief perspective from the front line</article-title><source>J&#x000a0;Infect</source><volume>80</volume><year>2020</year><fpage>373</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">32109444</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Chafekar</surname><given-names>A.</given-names></name><name><surname>Fielding</surname><given-names>B.C.</given-names></name><name><surname>MERS-CoV</surname></name></person-group><article-title>Understanding the latest human coronavirus threat</article-title><source>Viruses</source><volume>10</volume><year>2018</year></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Jhaveri</surname><given-names>R.</given-names></name></person-group><article-title>Echoes of 2009 H1N1 influenza pandemic in the COVID pandemic</article-title><source>Clin Therapeut</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.clinthera.2020.04.003</pub-id><comment>[online ahead of print]</comment></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Girard</surname><given-names>M.P.</given-names></name><name><surname>Tam</surname><given-names>J.S.</given-names></name><name><surname>Assossou</surname><given-names>O.M.</given-names></name><name><surname>Kieny</surname><given-names>M.P.</given-names></name></person-group><article-title>The 2009 A (H1N1) influenza virus pandemic: a review</article-title><source>Vaccine</source><volume>28</volume><year>2010</year><fpage>4895</fpage><lpage>4902</lpage><pub-id pub-id-type="pmid">20553769</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Chuah</surname><given-names>C.X.P.</given-names></name><name><surname>Lim</surname><given-names>R.L.</given-names></name><name><surname>Chen</surname><given-names>M.I.C.</given-names></name></person-group><article-title>Investigating the legacy of the 1918 influenza pandemic in age-related seroepidemiology and immune responses to subsequent influenza A(H1N1) viruses through a structural equation model</article-title><source>Am J Epidemiol</source><volume>187</volume><year>2018</year><fpage>2530</fpage><lpage>2540</lpage><pub-id pub-id-type="pmid">30165573</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Saglanmak</surname><given-names>N.</given-names></name><name><surname>Andreasen</surname><given-names>V.</given-names></name><name><surname>Simonsen</surname><given-names>L.</given-names></name><name><surname>Molbak</surname><given-names>K.</given-names></name><name><surname>Miller</surname><given-names>M.A.</given-names></name><name><surname>Viboud</surname><given-names>C.</given-names></name></person-group><article-title>Gradual changes in the age distribution of excess deaths in the years following the 1918 influenza pandemic in Copenhagen: using epidemiological evidence to detect antigenic drift</article-title><source>Vaccine</source><volume>29</volume><issue>Suppl 2</issue><year>2011</year><fpage>B42</fpage><lpage>B48</lpage><pub-id pub-id-type="pmid">21757103</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Xiao</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name></person-group><article-title>Research progress on human infection with avian influenza H7N9</article-title><source>Front Med</source><volume>14</volume><year>2020</year><fpage>8</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">31989396</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Cao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Bai</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Hu</surname><given-names>S.X.</given-names></name></person-group><article-title>Cross-neutralizing anti-hemagglutinin antibodies isolated from patients infected with avian influenza A (H5N1) virus</article-title><source>Biomed Environ Sci</source><volume>33</volume><year>2020</year><fpage>103</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">32131957</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>M.</given-names></name><name><surname>Herfst</surname><given-names>S.</given-names></name><name><surname>Sorrell</surname><given-names>E.M.</given-names></name><name><surname>Schrauwen</surname><given-names>E.J.</given-names></name><name><surname>Linster</surname><given-names>M.</given-names></name><name><surname>De Graaf</surname><given-names>M.</given-names></name></person-group><article-title>Transmission of influenza A/H5N1 viruses in mammals</article-title><source>Virus Res</source><volume>178</volume><year>2013</year><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">23954580</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Tanner</surname><given-names>W.D.</given-names></name><name><surname>Toth</surname><given-names>D.J.</given-names></name><name><surname>Gundlapalli</surname><given-names>A.V.</given-names></name></person-group><article-title>The pandemic potential of avian influenza A(H7N9) virus: a review</article-title><source>Epidemiol Infect</source><volume>143</volume><year>2015</year><fpage>3359</fpage><lpage>3374</lpage><pub-id pub-id-type="pmid">26205078</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Algahtani</surname><given-names>H.</given-names></name><name><surname>Subahi</surname><given-names>A.</given-names></name><name><surname>Shirah</surname><given-names>B.</given-names></name></person-group><article-title>Neurological complications of Middle East respiratory syndrome coronavirus: a report of two cases and review of the literature</article-title><source>Case Rep Neurol Med</source><volume>2016</volume><year>2016</year><fpage>3502683</fpage><pub-id pub-id-type="pmid">27239356</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>Y.</given-names></name><name><surname>Shang</surname><given-names>J.</given-names></name><name><surname>Graham</surname><given-names>R.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus</article-title><source>J&#x000a0;Virol</source><volume>94</volume><year>2020</year></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Corbett</surname><given-names>K.S.</given-names></name><name><surname>Goldsmith</surname><given-names>J.A.</given-names></name><name><surname>Hsieh</surname><given-names>C.L.</given-names></name><name><surname>Abiona</surname><given-names>O.</given-names></name></person-group><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source>Science</source><volume>367</volume><year>2020</year><fpage>1260</fpage><lpage>1263</lpage><pub-id pub-id-type="pmid">32075877</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Skowronski</surname><given-names>D.M.</given-names></name><name><surname>Astell</surname><given-names>C.</given-names></name><name><surname>Brunham</surname><given-names>R.C.</given-names></name><name><surname>Low</surname><given-names>D.E.</given-names></name><name><surname>Petric</surname><given-names>M.</given-names></name><name><surname>Roper</surname><given-names>R.L.</given-names></name></person-group><article-title>Severe acute respiratory syndrome (SARS): a year in review</article-title><source>Annu Rev Med</source><volume>56</volume><year>2005</year><fpage>357</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">15660517</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>C.I.</given-names></name><name><surname>Barclay</surname><given-names>W.S.</given-names></name><name><surname>Zambon</surname><given-names>M.C.</given-names></name><name><surname>Pickles</surname><given-names>R.J.</given-names></name></person-group><article-title>Infection of human airway epithelium by human and avian strains of influenza a virus</article-title><source>J&#x000a0;Virol</source><volume>80</volume><year>2006</year><fpage>8060</fpage><lpage>8068</lpage><pub-id pub-id-type="pmid">16873262</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="other" id="sref48"><ext-link ext-link-type="uri" xlink:href="https://www.who.int/influenza/human_animal_interface/influenza_h7n9/RiskAssessment_H7N9_23Feb20115.pdf?ua=1" id="intref0015">https://www.who.int/influenza/human_animal_interface/influenza_h7n9/RiskAssessment_H7N9_23Feb20115.pdf?ua=1</ext-link></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Krammer</surname><given-names>F.</given-names></name><name><surname>Smith</surname><given-names>G.J.D.</given-names></name><name><surname>Fouchier</surname><given-names>R.A.M.</given-names></name><name><surname>Peiris</surname><given-names>M.</given-names></name><name><surname>Kedzierska</surname><given-names>K.</given-names></name><name><surname>Doherty</surname><given-names>P.C.</given-names></name></person-group><article-title>Influenza</article-title><source>Nat Rev Dis Primers</source><volume>4</volume><year>2018</year><fpage>3</fpage><pub-id pub-id-type="pmid">29955068</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="other" id="sref50"><ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/don/2010_08_06/en" id="intref0020">https://www.who.int/csr/don/2010_08_06/en</ext-link></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="other" id="sref51"><ext-link ext-link-type="uri" xlink:href="https://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/" id="intref0025">https://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/</ext-link></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Su</surname><given-names>S.</given-names></name><name><surname>Wong</surname><given-names>G.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Lai</surname><given-names>A.C.K.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name></person-group><article-title>Epidemiology, genetic recombination, and pathogenesis of coronaviruses</article-title><source>Trends Microbiol</source><volume>24</volume><year>2016</year><fpage>490</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">27012512</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Corman</surname><given-names>V.M.</given-names></name><name><surname>Muth</surname><given-names>D.</given-names></name><name><surname>Niemeyer</surname><given-names>D.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name></person-group><article-title>Hosts and sources of endemic human coronaviruses</article-title><source>Adv Virus Res</source><volume>100</volume><year>2018</year><fpage>163</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">29551135</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Q.S.</given-names></name><name><surname>Zhong</surname><given-names>J.S.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>J.Y.</given-names></name></person-group><article-title>Clinical and epidemiological characteristics of 245 cases of influenza A (H3N2)</article-title><source>Zhonghua Jiehe He Huxi Zazhi</source><volume>42</volume><year>2019</year><fpage>510</fpage><lpage>514</lpage><pub-id pub-id-type="pmid">31365967</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Rodriguez-Morales</surname><given-names>A.J.</given-names></name><name><surname>Cardona-Ospina</surname><given-names>J.A.</given-names></name><name><surname>Gutierrez-Ocampo</surname><given-names>E.</given-names></name><name><surname>Villamizar-Pena</surname><given-names>R.</given-names></name><name><surname>Holguin-Rivera</surname><given-names>Y.</given-names></name><name><surname>Escalera-Antezana</surname><given-names>J.P.</given-names></name></person-group><article-title>Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis</article-title><source>Trav Med Infect Dis</source><year>2020</year><fpage>101623</fpage><pub-id pub-id-type="doi">10.1016/j.tmaid.2020.101623</pub-id><comment>[online ahead of print]</comment></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Guan</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Tong</surname><given-names>Y.</given-names></name></person-group><article-title>Early transmission dynamics in wuhan, China, of novel coronavirus-infected pneumonia</article-title><source>N&#x000a0;Engl J Med</source><volume>382</volume><year>2020</year><fpage>1199</fpage><lpage>1207</lpage><pub-id pub-id-type="pmid">31995857</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>N.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Qu</surname><given-names>J.</given-names></name><name><surname>Gong</surname><given-names>F.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name></person-group><article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>507</fpage><lpage>513</lpage><pub-id pub-id-type="pmid">32007143</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Senga</surname><given-names>M.</given-names></name><name><surname>Arabi</surname><given-names>Y.M.</given-names></name><name><surname>Fowler</surname><given-names>R.A.</given-names></name></person-group><article-title>Clinical spectrum of the Middle East respiratory syndrome coronavirus (MERS-CoV)</article-title><source>J&#x000a0;Infect Public Health</source><volume>10</volume><year>2017</year><fpage>191</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">27140697</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Memish</surname><given-names>Z.A.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name><name><surname>Van Kerkhove</surname><given-names>M.D.</given-names></name><name><surname>Zumla</surname><given-names>A.</given-names></name></person-group><article-title>Middle East respiratory syndrome</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>1063</fpage><lpage>1077</lpage><pub-id pub-id-type="pmid">32145185</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Assiri</surname><given-names>A.</given-names></name><name><surname>Al-Tawfiq</surname><given-names>J.A.</given-names></name><name><surname>Al-Rabeeah</surname><given-names>A.A.</given-names></name><name><surname>Al-Rabiah</surname><given-names>F.A.</given-names></name><name><surname>Al-Hajjar</surname><given-names>S.</given-names></name><name><surname>Al-Barrak</surname><given-names>A.</given-names></name></person-group><article-title>Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study</article-title><source>Lancet Infect Dis</source><volume>13</volume><year>2013</year><fpage>752</fpage><lpage>761</lpage><pub-id pub-id-type="pmid">23891402</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>D.S.C.</given-names></name><name><surname>Zumla</surname><given-names>A.</given-names></name></person-group><article-title>Severe acute respiratory syndrome: historical, epidemiologic, and clinical features</article-title><source>Infect Dis Clin</source><volume>33</volume><year>2019</year><fpage>869</fpage><lpage>889</lpage></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>G.M.</given-names></name><name><surname>Hedley</surname><given-names>A.J.</given-names></name><name><surname>Ho</surname><given-names>L.M.</given-names></name><name><surname>Chau</surname><given-names>P.</given-names></name><name><surname>Wong</surname><given-names>I.O.</given-names></name><name><surname>Thach</surname><given-names>T.Q.</given-names></name></person-group><article-title>The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients</article-title><source>Ann Intern Med</source><volume>141</volume><year>2004</year><fpage>662</fpage><lpage>673</lpage><pub-id pub-id-type="pmid">15520422</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name><surname>Booth</surname><given-names>C.M.</given-names></name><name><surname>Matukas</surname><given-names>L.M.</given-names></name><name><surname>Tomlinson</surname><given-names>G.A.</given-names></name><name><surname>Rachlis</surname><given-names>A.R.</given-names></name><name><surname>Rose</surname><given-names>D.B.</given-names></name><name><surname>Dwosh</surname><given-names>H.A.</given-names></name></person-group><article-title>Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area</article-title><source>J&#x000a0;Am Med Assoc</source><volume>289</volume><year>2003</year><fpage>2801</fpage><lpage>2809</lpage></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>J.S.</given-names></name><name><surname>Chu</surname><given-names>C.M.</given-names></name><name><surname>Cheng</surname><given-names>V.C.</given-names></name><name><surname>Chan</surname><given-names>K.S.</given-names></name><name><surname>Hung</surname><given-names>I.F.</given-names></name><name><surname>Poon</surname><given-names>L.L.</given-names></name></person-group><article-title>Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study</article-title><source>Lancet</source><volume>361</volume><year>2003</year><fpage>1767</fpage><lpage>1772</lpage><pub-id pub-id-type="pmid">12781535</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Ding</surname><given-names>W.</given-names></name><name><surname>Jia</surname><given-names>H.</given-names></name><name><surname>Chan</surname><given-names>J.F.</given-names></name></person-group><article-title>Clinical, virological, and histopathological manifestations of fatal human infections by avian influenza A(H7N9) virus</article-title><source>Clin Infect Dis</source><volume>57</volume><year>2013</year><fpage>1449</fpage><lpage>1457</lpage><pub-id pub-id-type="pmid">23943822</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Cowling</surname><given-names>B.J.</given-names></name><name><surname>Feng</surname><given-names>L.</given-names></name><name><surname>Lau</surname><given-names>E.H.</given-names></name><name><surname>Liao</surname><given-names>Q.</given-names></name><name><surname>Tsang</surname><given-names>T.K.</given-names></name></person-group><article-title>Human infection with avian influenza A H7N9 virus: an assessment of clinical severity</article-title><source>Lancet</source><volume>382</volume><year>2013</year><fpage>138</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">23803487</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>H.N.</given-names></name><name><surname>Lu</surname><given-names>H.Z.</given-names></name><name><surname>Cao</surname><given-names>B.</given-names></name><name><surname>Du</surname><given-names>B.</given-names></name><name><surname>Shang</surname><given-names>H.</given-names></name><name><surname>Gan</surname><given-names>J.H.</given-names></name></person-group><article-title>Clinical findings in 111 cases of influenza A (H7N9) virus infection</article-title><source>N&#x000a0;Engl J Med</source><volume>368</volume><year>2013</year><fpage>2277</fpage><lpage>2285</lpage><pub-id pub-id-type="pmid">23697469</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name></person-group><article-title>Clinical features and factors associated with outcomes of patients infected with a Novel Influenza A (H7N9) virus: a preliminary study</article-title><source>PloS One</source><volume>8</volume><year>2013</year><object-id pub-id-type="publisher-id">e73362</object-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name><surname>Poeppl</surname><given-names>W.</given-names></name><name><surname>Hell</surname><given-names>M.</given-names></name><name><surname>Herkner</surname><given-names>H.</given-names></name><name><surname>Stoiser</surname><given-names>B.</given-names></name><name><surname>Fritsche</surname><given-names>G.</given-names></name><name><surname>Schurz-Bamieh</surname><given-names>N.</given-names></name></person-group><article-title>Clinical aspects of 2009 pandemic influenza A (H1N1) virus infection in Austria</article-title><source>Infection</source><volume>39</volume><year>2011</year><fpage>341</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">21544585</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>M.</given-names></name><name><surname>Dennis</surname><given-names>A.</given-names></name><name><surname>Flutter</surname><given-names>C.</given-names></name><name><surname>Khan</surname><given-names>Z.</given-names></name></person-group><article-title>Pandemic (H1N1) 2009 influenza</article-title><source>Br J Anaesth</source><volume>104</volume><year>2010</year><fpage>128</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">20053625</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name><surname>Khandaker</surname><given-names>G.</given-names></name><name><surname>Dierig</surname><given-names>A.</given-names></name><name><surname>Rashid</surname><given-names>H.</given-names></name><name><surname>King</surname><given-names>C.</given-names></name><name><surname>Heron</surname><given-names>L.</given-names></name><name><surname>Booy</surname><given-names>R.</given-names></name></person-group><article-title>Systematic review of clinical and epidemiological features of the pandemic influenza A (H1N1) 2009</article-title><source>Influenza Other Respir Viruses</source><volume>5</volume><year>2011</year><fpage>148</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">21477133</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>P.P.</given-names></name><name><surname>Cinti</surname><given-names>S.</given-names></name><name><surname>Kazerooni</surname><given-names>E.A.</given-names></name></person-group><article-title>Chest radiographic and CT findings in novel swine-origin influenza A (H1N1) virus (S-OIV) infection</article-title><source>AJR Am J Roentgenol</source><volume>193</volume><year>2009</year><fpage>1488</fpage><lpage>1493</lpage><pub-id pub-id-type="pmid">19933638</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>J.S.</given-names></name><name><surname>Poon</surname><given-names>L.L.</given-names></name><name><surname>Guan</surname><given-names>Y.</given-names></name></person-group><article-title>Emergence of a novel swine-origin influenza A virus (S-OIV) H1N1 virus in humans</article-title><source>J&#x000a0;Clin Virol</source><volume>45</volume><year>2009</year><fpage>169</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">19540800</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name><surname>Liem</surname><given-names>N.T.</given-names></name><name><surname>Tung</surname><given-names>C.V.</given-names></name><name><surname>Hien</surname><given-names>N.D.</given-names></name><name><surname>Hien</surname><given-names>T.T.</given-names></name><name><surname>Chau</surname><given-names>N.Q.</given-names></name><name><surname>Long</surname><given-names>H.T.</given-names></name></person-group><article-title>Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006</article-title><source>Clin Infect Dis</source><volume>48</volume><year>2009</year><fpage>1639</fpage><lpage>1646</lpage><pub-id pub-id-type="pmid">19435433</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>D.S.</given-names></name></person-group><article-title>Review of clinical symptoms and spectrum in humans with influenza A/H5N1 infection</article-title><source>Respirology</source><volume>13</volume><issue>Suppl 1</issue><year>2008</year><fpage>S10</fpage><lpage>S13</lpage><pub-id pub-id-type="pmid">18366521</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Gao</surname><given-names>Z.</given-names></name><name><surname>Feng</surname><given-names>Z.</given-names></name><name><surname>Shu</surname><given-names>Y.</given-names></name><name><surname>Xiang</surname><given-names>N.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name></person-group><article-title>Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China</article-title><source>PloS One</source><volume>3</volume><year>2008</year><fpage>e2985</fpage><pub-id pub-id-type="pmid">18716658</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S.F.</given-names></name><name><surname>Tuo</surname><given-names>J.L.</given-names></name><name><surname>Huang</surname><given-names>X.B.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>D.M.</given-names></name><name><surname>Zhou</surname><given-names>K.</given-names></name></person-group><article-title>Epidemiology characteristics of human coronaviruses in patients with respiratory infection symptoms and phylogenetic analysis of HCoV-OC43 during 2010-2015 in Guangzhou</article-title><source>PloS One</source><volume>13</volume><year>2018</year><object-id pub-id-type="publisher-id">e0191789</object-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name><surname>Cabeca</surname><given-names>T.K.</given-names></name><name><surname>Granato</surname><given-names>C.</given-names></name><name><surname>Bellei</surname><given-names>N.</given-names></name></person-group><article-title>Epidemiological and clinical features of human coronavirus infections among different subsets of patients</article-title><source>Influenza Other Respir Viruses</source><volume>7</volume><year>2013</year><fpage>1040</fpage><lpage>1047</lpage><pub-id pub-id-type="pmid">23462106</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name><surname>Pyrc</surname><given-names>K.</given-names></name><name><surname>Berkhout</surname><given-names>B.</given-names></name><name><surname>van der Hoek</surname><given-names>L.</given-names></name></person-group><article-title>The novel human coronaviruses NL63 and HKU1</article-title><source>J&#x000a0;Virol</source><volume>81</volume><year>2007</year><fpage>3051</fpage><lpage>3057</lpage><pub-id pub-id-type="pmid">17079323</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name><surname>Wie</surname><given-names>S.H.</given-names></name><name><surname>So</surname><given-names>B.H.</given-names></name><name><surname>Song</surname><given-names>J.Y.</given-names></name><name><surname>Cheong</surname><given-names>H.J.</given-names></name><name><surname>Seo</surname><given-names>Y.B.</given-names></name><name><surname>Choi</surname><given-names>S.H.</given-names></name></person-group><article-title>A&#x000a0;comparison of the clinical and epidemiological characteristics of adult patients with laboratory-confirmed influenza A or B during the 2011-2012 influenza season in Korea: a multi-center study</article-title><source>PloS One</source><volume>8</volume><year>2013</year><object-id pub-id-type="publisher-id">e62685</object-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name><surname>Irving</surname><given-names>S.A.</given-names></name><name><surname>Patel</surname><given-names>D.C.</given-names></name><name><surname>Kieke</surname><given-names>B.A.</given-names></name><name><surname>Donahue</surname><given-names>J.G.</given-names></name><name><surname>Vandermause</surname><given-names>M.F.</given-names></name><name><surname>Shay</surname><given-names>D.K.</given-names></name></person-group><article-title>Comparison of clinical features and outcomes of medically attended influenza A and influenza B in a defined population over four seasons: 2004-2005 through 2007-2008</article-title><source>Influenza Other Respir Viruses</source><volume>6</volume><year>2012</year><fpage>37</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">21668663</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name><surname>Rogo</surname><given-names>L.D.</given-names></name><name><surname>Rezaei</surname><given-names>F.</given-names></name><name><surname>Marashi</surname><given-names>S.M.</given-names></name><name><surname>Yekaninejad</surname><given-names>M.S.</given-names></name><name><surname>Naseri</surname><given-names>M.</given-names></name><name><surname>Ghavami</surname><given-names>N.</given-names></name></person-group><article-title>Seasonal influenza A/H3N2 virus infection and IL-1Beta, IL-10, IL-17, and IL-28 polymorphisms in Iranian population</article-title><source>J&#x000a0;Med Virol</source><volume>88</volume><year>2016</year><fpage>2078</fpage><lpage>2084</lpage><pub-id pub-id-type="pmid">27155288</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name><surname>Kaji</surname><given-names>M.</given-names></name><name><surname>Watanabe</surname><given-names>A.</given-names></name><name><surname>Aizawa</surname><given-names>H.</given-names></name></person-group><article-title>Differences in clinical features between influenza A H1N1, A H3N2, and B in adult patients</article-title><source>Respirology</source><volume>8</volume><year>2003</year><fpage>231</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">12753540</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Xia</surname><given-names>Y.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Su</surname><given-names>H.</given-names></name></person-group><article-title>Prediction of H7N9 epidemic in China</article-title><source>Chin Med J</source><volume>127</volume><year>2014</year><fpage>254</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">24438612</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Gu</surname><given-names>D.</given-names></name><name><surname>Ouyang</surname><given-names>X.</given-names></name><name><surname>Xie</surname><given-names>W.</given-names></name></person-group><article-title>Proinflammatory effects of the hemagglutinin protein of the avian influenza A (H7N9) virus and microRNAmediated homeostasis response in THP1 cells</article-title><source>Mol Med Rep</source><volume>12</volume><year>2015</year><fpage>6241</fpage><lpage>6246</lpage><pub-id pub-id-type="pmid">26238163</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name></person-group><article-title>Pathological findings of COVID-19 associated with acute respiratory distress syndrome</article-title><source>Lancet Respir Med</source><volume>8</volume><year>2020</year><fpage>420</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">32085846</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>H.</given-names></name><name><surname>Han</surname><given-names>X.</given-names></name><name><surname>Jiang</surname><given-names>N.</given-names></name><name><surname>Cao</surname><given-names>Y.</given-names></name><name><surname>Alwalid</surname><given-names>O.</given-names></name><name><surname>Gu</surname><given-names>J.</given-names></name></person-group><article-title>Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study</article-title><source>Lancet Infect Dis</source><volume>20</volume><year>2020</year><fpage>425</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">32105637</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name><surname>Barton</surname><given-names>L.M.</given-names></name><name><surname>Duval</surname><given-names>E.J.</given-names></name><name><surname>Stroberg</surname><given-names>E.</given-names></name><name><surname>Ghosh</surname><given-names>S.</given-names></name><name><surname>Mukhopadhyay</surname><given-names>S.</given-names></name></person-group><article-title>COVID-19 autopsies, Oklahoma, USA</article-title><source>Am J Clin Pathol</source><volume>153</volume><year>2020</year><fpage>725</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">32275742</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>D.L.</given-names></name><name><surname>Al Hosani</surname><given-names>F.</given-names></name><name><surname>Keating</surname><given-names>M.K.</given-names></name><name><surname>Gerber</surname><given-names>S.I.</given-names></name><name><surname>Jones</surname><given-names>T.L.</given-names></name><name><surname>Metcalfe</surname><given-names>M.G.</given-names></name></person-group><article-title>Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014</article-title><source>Am J Pathol</source><volume>186</volume><year>2016</year><fpage>652</fpage><lpage>658</lpage><pub-id pub-id-type="pmid">26857507</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name><surname>Nicholls</surname><given-names>J.M.</given-names></name><name><surname>Poon</surname><given-names>L.L.</given-names></name><name><surname>Lee</surname><given-names>K.C.</given-names></name><name><surname>Ng</surname><given-names>W.F.</given-names></name><name><surname>Lai</surname><given-names>S.T.</given-names></name><name><surname>Leung</surname><given-names>C.Y.</given-names></name></person-group><article-title>Lung pathology of fatal severe acute respiratory syndrome</article-title><source>Lancet</source><volume>361</volume><year>2003</year><fpage>1773</fpage><lpage>1778</lpage><pub-id pub-id-type="pmid">12781536</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name><surname>Franks</surname><given-names>T.J.</given-names></name><name><surname>Chong</surname><given-names>P.Y.</given-names></name><name><surname>Chui</surname><given-names>P.</given-names></name><name><surname>Galvin</surname><given-names>J.R.</given-names></name><name><surname>Lourens</surname><given-names>R.M.</given-names></name><name><surname>Reid</surname><given-names>A.H.</given-names></name></person-group><article-title>Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore</article-title><source>Hum Pathol</source><volume>34</volume><year>2003</year><fpage>743</fpage><lpage>748</lpage><pub-id pub-id-type="pmid">14506633</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>J.</given-names></name><name><surname>Gong</surname><given-names>E.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Gao</surname><given-names>Z.</given-names></name><name><surname>Zhong</surname><given-names>Y.</given-names></name></person-group><article-title>Multiple organ infection and the pathogenesis of SARS</article-title><source>J&#x000a0;Exp Med</source><volume>202</volume><year>2005</year><fpage>415</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">16043521</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Zeng</surname><given-names>D.</given-names></name></person-group><article-title>Molecular pathology analyses of two fatal human infections of avian influenza A(H7N9) virus</article-title><source>J&#x000a0;Clin Pathol</source><volume>68</volume><year>2015</year><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">25378539</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name></person-group><article-title>Emerging H7N9 influenza A (novel reassortant avian-origin) pneumonia: radiologic findings</article-title><source>Radiology</source><volume>268</volume><year>2013</year><fpage>882</fpage><lpage>889</lpage><pub-id pub-id-type="pmid">23821754</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name><surname>Bal</surname><given-names>A.</given-names></name><name><surname>Suri</surname><given-names>V.</given-names></name><name><surname>Mishra</surname><given-names>B.</given-names></name><name><surname>Bhalla</surname><given-names>A.</given-names></name><name><surname>Agarwal</surname><given-names>R.</given-names></name><name><surname>Abrol</surname><given-names>A.</given-names></name></person-group><article-title>Pathology and virology findings in cases of fatal influenza A H1N1 virus infection in 2009-2010</article-title><source>Histopathology</source><volume>60</volume><year>2012</year><fpage>326</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">22211291</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name><surname>Mauad</surname><given-names>T.</given-names></name><name><surname>Hajjar</surname><given-names>L.A.</given-names></name><name><surname>Callegari</surname><given-names>G.D.</given-names></name><name><surname>da Silva</surname><given-names>L.F.</given-names></name><name><surname>Schout</surname><given-names>D.</given-names></name><name><surname>Galas</surname><given-names>F.R.</given-names></name></person-group><article-title>Lung pathology in fatal novel human influenza A (H1N1) infection</article-title><source>Am J Respir Crit Care Med</source><volume>181</volume><year>2010</year><fpage>72</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">19875682</pub-id></element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>L.</given-names></name><name><surname>Gu</surname><given-names>L.</given-names></name><name><surname>Cao</surname><given-names>B.</given-names></name><name><surname>Zhai</surname><given-names>X.L.</given-names></name><name><surname>Lu</surname><given-names>M.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name></person-group><article-title>Clinical features of pneumonia caused by 2009 influenza A(H1N1) virus in Beijing, China</article-title><source>Chest</source><volume>139</volume><year>2011</year><fpage>1156</fpage><lpage>1164</lpage><pub-id pub-id-type="pmid">20864615</pub-id></element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name><surname>Nakajima</surname><given-names>N.</given-names></name><name><surname>Van Tin</surname><given-names>N.</given-names></name><name><surname>Sato</surname><given-names>Y.</given-names></name><name><surname>Thach</surname><given-names>H.N.</given-names></name><name><surname>Katano</surname><given-names>H.</given-names></name><name><surname>Diep</surname><given-names>P.H.</given-names></name></person-group><article-title>Pathological study of archival lung tissues from five fatal cases of avian H5N1 influenza in Vietnam</article-title><source>Mod Pathol</source><volume>26</volume><year>2013</year><fpage>357</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">23174938</pub-id></element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name><surname>Korteweg</surname><given-names>C.</given-names></name><name><surname>Gu</surname><given-names>J.</given-names></name></person-group><article-title>Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1) infection in humans</article-title><source>Am J Pathol</source><volume>172</volume><year>2008</year><fpage>1155</fpage><lpage>1170</lpage><pub-id pub-id-type="pmid">18403604</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name><surname>Uiprasertkul</surname><given-names>M.</given-names></name><name><surname>Kitphati</surname><given-names>R.</given-names></name><name><surname>Puthavathana</surname><given-names>P.</given-names></name><name><surname>Kriwong</surname><given-names>R.</given-names></name><name><surname>Kongchanagul</surname><given-names>A.</given-names></name><name><surname>Ungchusak</surname><given-names>K.</given-names></name></person-group><article-title>Apoptosis and pathogenesis of avian influenza A (H5N1) virus in humans</article-title><source>Emerg Infect Dis</source><volume>13</volume><year>2007</year><fpage>708</fpage><lpage>712</lpage><pub-id pub-id-type="pmid">17553248</pub-id></element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>J.S.</given-names></name><name><surname>Yu</surname><given-names>W.C.</given-names></name><name><surname>Leung</surname><given-names>C.W.</given-names></name><name><surname>Cheung</surname><given-names>C.Y.</given-names></name><name><surname>Ng</surname><given-names>W.F.</given-names></name><name><surname>Nicholls</surname><given-names>J.M.</given-names></name></person-group><article-title>Re-emergence of fatal human influenza A subtype H5N1 disease</article-title><source>Lancet</source><volume>363</volume><year>2004</year><fpage>617</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">14987888</pub-id></element-citation></ref><ref id="bib103"><label>103</label><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>P.C.</given-names></name><name><surname>Lau</surname><given-names>S.K.</given-names></name><name><surname>Tsoi</surname><given-names>H.W.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Poon</surname><given-names>R.W.</given-names></name><name><surname>Chu</surname><given-names>C.M.</given-names></name></person-group><article-title>Clinical and molecular epidemiological features of coronavirus HKU1-associated community-acquired pneumonia</article-title><source>J&#x000a0;Infect Dis</source><volume>192</volume><year>2005</year><fpage>1898</fpage><lpage>1907</lpage><pub-id pub-id-type="pmid">16267760</pub-id></element-citation></ref><ref id="bib104"><label>104</label><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name><surname>Vabret</surname><given-names>A.</given-names></name><name><surname>Mourez</surname><given-names>T.</given-names></name><name><surname>Gouarin</surname><given-names>S.</given-names></name><name><surname>Petitjean</surname><given-names>J.</given-names></name><name><surname>Freymuth</surname><given-names>F.</given-names></name></person-group><article-title>An outbreak of coronavirus OC43 respiratory infection in Normandy, France</article-title><source>Clin Infect Dis</source><volume>36</volume><year>2003</year><fpage>985</fpage><lpage>989</lpage><pub-id pub-id-type="pmid">12684910</pub-id></element-citation></ref><ref id="bib105"><label>105</label><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name><surname>Pene</surname><given-names>F.</given-names></name><name><surname>Merlat</surname><given-names>A.</given-names></name><name><surname>Vabret</surname><given-names>A.</given-names></name><name><surname>Rozenberg</surname><given-names>F.</given-names></name><name><surname>Buzyn</surname><given-names>A.</given-names></name><name><surname>Dreyfus</surname><given-names>F.</given-names></name></person-group><article-title>Coronavirus 229E-related pneumonia in immunocompromised patients</article-title><source>Clin Infect Dis</source><volume>37</volume><year>2003</year><fpage>929</fpage><lpage>932</lpage><pub-id pub-id-type="pmid">13130404</pub-id></element-citation></ref><ref id="bib106"><label>106</label><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name><surname>Ebihara</surname><given-names>T.</given-names></name><name><surname>Endo</surname><given-names>R.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Ishiguro</surname><given-names>N.</given-names></name><name><surname>Kikuta</surname><given-names>H.</given-names></name></person-group><article-title>Detection of human coronavirus NL63 in young children with bronchiolitis</article-title><source>J&#x000a0;Med Virol</source><volume>75</volume><year>2005</year><fpage>463</fpage><lpage>465</lpage><pub-id pub-id-type="pmid">15648061</pub-id></element-citation></ref><ref id="bib107"><label>107</label><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name><surname>Guarner</surname><given-names>J.</given-names></name><name><surname>Falcon-Escobedo</surname><given-names>R.</given-names></name></person-group><article-title>Comparison of the pathology caused by H1N1, H5N1, and H3N2 influenza viruses</article-title><source>Arch Med Res</source><volume>40</volume><year>2009</year><fpage>655</fpage><lpage>661</lpage><pub-id pub-id-type="pmid">20304252</pub-id></element-citation></ref><ref id="bib108"><label>108</label><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>C.B.</given-names></name></person-group><source>Ribavirin. Infect Dis Newsl (N Y)</source><volume>4</volume><year>1985</year><fpage>73</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">32336861</pub-id></element-citation></ref><ref id="bib109"><label>109</label><element-citation publication-type="journal" id="sref109"><person-group person-group-type="author"><name><surname>Dyall</surname><given-names>J.</given-names></name><name><surname>Gross</surname><given-names>R.</given-names></name><name><surname>Kindrachuk</surname><given-names>J.</given-names></name><name><surname>Johnson</surname><given-names>R.F.</given-names></name><name><surname>Olinger</surname><given-names>G.G.</given-names><suffix>Jr.</suffix></name><name><surname>Hensley</surname><given-names>L.E.</given-names></name></person-group><article-title>Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies</article-title><source>Drugs</source><volume>77</volume><year>2017</year><fpage>1935</fpage><lpage>1966</lpage><pub-id pub-id-type="pmid">29143192</pub-id></element-citation></ref><ref id="bib110"><label>110</label><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name><surname>Ledford</surname><given-names>H.</given-names></name></person-group><article-title>Hopes rise for coronavirus drug remdesivir</article-title><source>Nature</source><year>2020</year><pub-id pub-id-type="doi">10.1038/d41586-020-01295-8</pub-id><comment>[online ahead of print]</comment></element-citation></ref><ref id="bib111"><label>111</label><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y.C.</given-names></name><name><surname>Deng</surname><given-names>Q.X.</given-names></name><name><surname>Dai</surname><given-names>S.X.</given-names></name></person-group><article-title>Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: an evaluation of the evidence</article-title><source>Trav Med Infect Dis</source><year>2020</year><fpage>101647</fpage></element-citation></ref><ref id="bib112"><label>112</label><element-citation publication-type="other" id="sref112"><ext-link ext-link-type="uri" xlink:href="http://19/remdesivir-clinical-trials%20hwgcpa-g-hc" id="intref0030">19/remdesivir-clinical-trials hwgcpa-g-hc</ext-link></element-citation></ref><ref id="bib113"><label>113</label><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name><surname>Sinha</surname><given-names>N.</given-names></name><name><surname>Balayla</surname><given-names>G.</given-names></name></person-group><article-title>Hydroxychloroquine and covid-19</article-title><source>Postgrad Med</source><year>2020</year><pub-id pub-id-type="doi">10.1136/postgradmedj-2020-137785</pub-id><comment>[online ahead of print]</comment></element-citation></ref><ref id="bib114"><label>114</label><element-citation publication-type="journal" id="sref114"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>B.B.</given-names></name></person-group><article-title>Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review</article-title><source>J&#x000a0;Toxicol Environ Health B Crit Rev</source><volume>23</volume><year>2020</year><fpage>177</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">32281481</pub-id></element-citation></ref><ref id="bib115"><label>115</label><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name><surname>Chowdhury</surname><given-names>M.S.</given-names></name><name><surname>Rathod</surname><given-names>J.</given-names></name><name><surname>Gernsheimer</surname><given-names>J.</given-names></name></person-group><article-title>A&#x000a0;rapid systematic review of clinical trials utilizing chloroquine and hydroxychloroquine as a treatment for COVID-19</article-title><source>Acad Emerg Med</source><year>2020</year><pub-id pub-id-type="doi">10.1111/acem.14005</pub-id><comment>[online ahead of print]</comment></element-citation></ref><ref id="bib116"><label>116</label><element-citation publication-type="journal" id="sref116"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>K.W.</given-names></name><name><surname>Wong</surname><given-names>V.T.</given-names></name><name><surname>Tang</surname><given-names>S.C.W.</given-names></name></person-group><article-title>COVID-19: an update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-western medicine for the management of 2019 novel coronavirus disease</article-title><source>Am J Chin Med</source><year>2020</year><fpage>1</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">32054304</pub-id></element-citation></ref><ref id="bib117"><label>117</label><element-citation publication-type="journal" id="sref117"><person-group person-group-type="author"><name><surname>Pizzorno</surname><given-names>A.</given-names></name><name><surname>Padey</surname><given-names>B.</given-names></name><name><surname>Terrier</surname><given-names>O.</given-names></name><name><surname>Rosa-Calatrava</surname><given-names>M.</given-names></name></person-group><article-title>Drug repurposing approaches for the treatment of influenza viral infection: reviving old drugs to fight against a long-lived enemy</article-title><source>Front Immunol</source><volume>10</volume><year>2019</year><fpage>531</fpage><pub-id pub-id-type="pmid">30941148</pub-id></element-citation></ref><ref id="bib118"><label>118</label><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Qian</surname><given-names>Y.</given-names></name><name><surname>Qiu</surname><given-names>J.</given-names></name></person-group><article-title>Simultaneous determination of amantadine and rimantadine in feed by liquid chromatography-Qtrap mass spectrometry with information-dependent acquisition</article-title><source>Anal Bioanal Chem</source><volume>410</volume><year>2018</year><fpage>5555</fpage><lpage>5565</lpage><pub-id pub-id-type="pmid">29651527</pub-id></element-citation></ref><ref id="bib119"><label>119</label><element-citation publication-type="journal" id="sref119"><person-group person-group-type="author"><name><surname>Tsuruoka</surname><given-names>Y.</given-names></name><name><surname>Nakajima</surname><given-names>T.</given-names></name><name><surname>Kanda</surname><given-names>M.</given-names></name><name><surname>Hayashi</surname><given-names>H.</given-names></name><name><surname>Matsushima</surname><given-names>Y.</given-names></name><name><surname>Yoshikawa</surname><given-names>S.</given-names></name></person-group><article-title>Simultaneous determination of amantadine, rimantadine, and memantine in processed products, chicken tissues, and eggs by liquid chromatography with tandem mass spectrometry</article-title><source>J&#x000a0;Chromatogr B Analyt Technol Biomed Life Sci</source><volume>1044&#x02013;1045</volume><year>2017</year><fpage>142</fpage><lpage>148</lpage></element-citation></ref><ref id="bib120"><label>120</label><element-citation publication-type="journal" id="sref120"><person-group person-group-type="author"><name><surname>Tejada</surname><given-names>S.</given-names></name><name><surname>Campogiani</surname><given-names>L.</given-names></name><name><surname>Sole-Lleonart</surname><given-names>C.</given-names></name><name><surname>Rello</surname><given-names>J.</given-names></name></person-group><article-title>Alternative regimens of neuraminidase inhibitors for therapy of hospitalized adults with influenza: a systematic review of randomized controlled trials</article-title><source>Adv Ther</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s12325-020-01347-5</pub-id><comment>[online ahead of print]</comment></element-citation></ref><ref id="bib121"><label>121</label><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name><surname>Doll</surname><given-names>M.K.</given-names></name><name><surname>Winters</surname><given-names>N.</given-names></name><name><surname>Boikos</surname><given-names>C.</given-names></name><name><surname>Kraicer-Melamed</surname><given-names>H.</given-names></name><name><surname>Gore</surname><given-names>G.</given-names></name><name><surname>Quach</surname><given-names>C.</given-names></name></person-group><article-title>Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses</article-title><source>J&#x000a0;Antimicrob Chemother</source><volume>72</volume><year>2017</year><fpage>2990</fpage><lpage>3007</lpage><pub-id pub-id-type="pmid">28961794</pub-id></element-citation></ref><ref id="bib122"><label>122</label><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name><surname>Abed</surname><given-names>Y.</given-names></name><name><surname>Pizzorno</surname><given-names>A.</given-names></name><name><surname>Bouhy</surname><given-names>X.</given-names></name><name><surname>Rheaume</surname><given-names>C.</given-names></name><name><surname>Boivin</surname><given-names>G.</given-names></name></person-group><article-title>Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in&#x000a0;vitro, in mice and in ferrets</article-title><source>J&#x000a0;Virol</source><volume>88</volume><year>2014</year><fpage>1652</fpage><lpage>1658</lpage><pub-id pub-id-type="pmid">24257597</pub-id></element-citation></ref><ref id="bib123"><label>123</label><element-citation publication-type="journal" id="sref123"><person-group person-group-type="author"><name><surname>Jarhult</surname><given-names>J.D.</given-names></name></person-group><article-title>Oseltamivir (Tamiflu((R))) in the environment, resistance development in influenza A viruses of dabbling ducks and the risk of transmission of an oseltamivir-resistant virus to humans - a review</article-title><source>Infect Ecol Epidemiol</source><volume>2</volume><year>2012</year></element-citation></ref><ref id="bib124"><label>124</label><element-citation publication-type="journal" id="sref124"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>G.</given-names></name><name><surname>Cihlar</surname><given-names>T.</given-names></name><name><surname>Oo</surname><given-names>C.</given-names></name><name><surname>Ho</surname><given-names>E.S.</given-names></name><name><surname>Prior</surname><given-names>K.</given-names></name><name><surname>Wiltshire</surname><given-names>H.</given-names></name></person-group><article-title>The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in&#x000a0;vivo and in&#x000a0;vitro studies</article-title><source>Drug Metab Dispos</source><volume>30</volume><year>2002</year><fpage>13</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">11744606</pub-id></element-citation></ref><ref id="bib125"><label>125</label><element-citation publication-type="journal" id="sref125"><person-group person-group-type="author"><name><surname>Kakuya</surname><given-names>F.</given-names></name><name><surname>Haga</surname><given-names>S.</given-names></name><name><surname>Okubo</surname><given-names>H.</given-names></name><name><surname>Fujiyasu</surname><given-names>H.</given-names></name><name><surname>Kinebuchi</surname><given-names>T.</given-names></name></person-group><article-title>Effectiveness of baloxavir marboxil against influenza in children</article-title><source>Pediatr Int</source><volume>61</volume><year>2019</year><fpage>616</fpage><lpage>618</lpage><pub-id pub-id-type="pmid">31195429</pub-id></element-citation></ref><ref id="bib126"><label>126</label><element-citation publication-type="journal" id="sref126"><person-group person-group-type="author"><name><surname>Locke</surname><given-names>S.C.</given-names></name><name><surname>Splawn</surname><given-names>L.M.</given-names></name><name><surname>Cho</surname><given-names>J.C.</given-names></name></person-group><article-title>Baloxavir marboxil: a novel cap-dependent endonuclease (CEN) inhibitor for the treatment of acute uncomplicated influenza</article-title><source>Drugs Today</source><volume>55</volume><year>2019</year><fpage>359</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">31250840</pub-id></element-citation></ref><ref id="bib127"><label>127</label><element-citation publication-type="journal" id="sref127"><person-group person-group-type="author"><name><surname>Koszalka</surname><given-names>P.</given-names></name><name><surname>Tilmanis</surname><given-names>D.</given-names></name><name><surname>Roe</surname><given-names>M.</given-names></name><name><surname>Vijaykrishna</surname><given-names>D.</given-names></name><name><surname>Hurt</surname><given-names>A.C.</given-names></name></person-group><article-title>Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018</article-title><source>Antivir Res</source><volume>164</volume><year>2019</year><fpage>91</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">30771405</pub-id></element-citation></ref><ref id="bib128"><label>128</label><element-citation publication-type="journal" id="sref128"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>K.E.</given-names></name></person-group><article-title>Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza</article-title><source>P&#x000a0;T</source><volume>44</volume><year>2019</year><fpage>9</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">30675086</pub-id></element-citation></ref><ref id="bib129"><label>129</label><element-citation publication-type="journal" id="sref129"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>Y.</given-names></name><name><surname>Komeno</surname><given-names>T.</given-names></name><name><surname>Nakamura</surname><given-names>T.</given-names></name></person-group><article-title>Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase</article-title><source>Proc Jpn Acad Ser B Phys Biol Sci</source><volume>93</volume><year>2017</year><fpage>449</fpage><lpage>463</lpage></element-citation></ref><ref id="bib130"><label>130</label><element-citation publication-type="journal" id="sref130"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Song</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Bei</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name></person-group><article-title>Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of Zika virus replication</article-title><source>Arch Virol</source><volume>162</volume><year>2017</year><fpage>2847</fpage><lpage>2853</lpage><pub-id pub-id-type="pmid">28597088</pub-id></element-citation></ref><ref id="bib131"><label>131</label><element-citation publication-type="journal" id="sref131"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>Q.Q.</given-names></name><name><surname>Huang</surname><given-names>W.J.</given-names></name><name><surname>Li</surname><given-names>X.Y.</given-names></name><name><surname>Cheng</surname><given-names>Y.H.</given-names></name><name><surname>Tan</surname><given-names>M.J.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name></person-group><article-title>Effectiveness of favipiravir (T-705) against wild-type and oseltamivir-resistant influenza B virus in mice</article-title><source>Virology</source><volume>545</volume><year>2020</year><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">32174453</pub-id></element-citation></ref><ref id="bib132"><label>132</label><element-citation publication-type="journal" id="sref132"><person-group person-group-type="author"><name><surname>Koshimichi</surname><given-names>H.</given-names></name><name><surname>Tsuda</surname><given-names>Y.</given-names></name><name><surname>Ishibashi</surname><given-names>T.</given-names></name><name><surname>Wajima</surname><given-names>T.</given-names></name></person-group><article-title>Population pharmacokinetic and exposure-response analyses of baloxavir marboxil in adults and adolescents including patients with influenza</article-title><source>J&#x000a0;Pharmaceut Sci</source><volume>108</volume><year>2019</year><fpage>1896</fpage><lpage>1904</lpage></element-citation></ref><ref id="bib133"><label>133</label><element-citation publication-type="journal" id="sref133"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name></person-group><article-title>Novel hemagglutinin-based influenza virus inhibitors</article-title><source>J&#x000a0;Thorac Dis</source><volume>5</volume><issue>Suppl 2</issue><year>2013</year><fpage>S149</fpage><lpage>S159</lpage><pub-id pub-id-type="pmid">23977436</pub-id></element-citation></ref><ref id="bib134"><label>134</label><element-citation publication-type="journal" id="sref134"><person-group person-group-type="author"><name><surname>Ilyushina</surname><given-names>N.A.</given-names></name><name><surname>Komatsu</surname><given-names>T.E.</given-names></name><name><surname>Ince</surname><given-names>W.L.</given-names></name><name><surname>Donaldson</surname><given-names>E.F.</given-names></name><name><surname>Lee</surname><given-names>N.</given-names></name><name><surname>O&#x02019;Rear</surname><given-names>J.J.</given-names></name></person-group><article-title>Influenza A virus hemagglutinin mutations associated with use of neuraminidase inhibitors correlate with decreased inhibition by anti-influenza antibodies</article-title><source>Virol J</source><volume>16</volume><year>2019</year><fpage>149</fpage><pub-id pub-id-type="pmid">31783761</pub-id></element-citation></ref><ref id="bib135"><label>135</label><element-citation publication-type="journal" id="sref135"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Ma</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>Inhibitors targeting the influenza virus hemagglutinin</article-title><source>Curr Med Chem</source><volume>22</volume><year>2015</year><fpage>1361</fpage><lpage>1382</lpage><pub-id pub-id-type="pmid">25723505</pub-id></element-citation></ref><ref id="bib136"><label>136</label><element-citation publication-type="journal" id="sref136"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>D.</given-names></name><name><surname>Luo</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Xie</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name></person-group><article-title>Potent influenza A virus entry inhibitors targeting a conserved region of hemagglutinin</article-title><source>Biochem Pharmacol</source><volume>144</volume><year>2017</year><fpage>35</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">28774731</pub-id></element-citation></ref><ref id="bib137"><label>137</label><element-citation publication-type="journal" id="sref137"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>X.T.</given-names></name><name><surname>Zhang</surname><given-names>X.X.</given-names></name><name><surname>Liu</surname><given-names>S.W.</given-names></name></person-group><article-title>Novel hemagglutinin-based influenza virus inhibitors</article-title><source>J&#x000a0;Thorac Dis</source><volume>5</volume><year>2013</year><fpage>S149</fpage><lpage>S159</lpage><pub-id pub-id-type="pmid">23977436</pub-id></element-citation></ref><ref id="bib138"><label>138</label><element-citation publication-type="journal" id="sref138"><person-group person-group-type="author"><name><surname>Salvatore</surname><given-names>M.</given-names></name><name><surname>Satlin</surname><given-names>M.J.</given-names></name><name><surname>Jacobs</surname><given-names>S.E.</given-names></name><name><surname>Jenkins</surname><given-names>S.G.</given-names></name><name><surname>Schuetz</surname><given-names>A.N.</given-names></name><name><surname>Moss</surname><given-names>R.B.</given-names></name></person-group><article-title>DAS181 for treatment of parainfluenza virus infections in hematopoietic stem cell transplant recipients at a single center</article-title><source>Biol Blood Marrow Transplant</source><volume>22</volume><year>2016</year><fpage>965</fpage><lpage>970</lpage><pub-id pub-id-type="pmid">26904972</pub-id></element-citation></ref><ref id="bib139"><label>139</label><element-citation publication-type="journal" id="sref139"><person-group person-group-type="author"><name><surname>Dhakal</surname><given-names>B.</given-names></name><name><surname>D&#x02019;Souza</surname><given-names>A.</given-names></name><name><surname>Pasquini</surname><given-names>M.</given-names></name><name><surname>Saber</surname><given-names>W.</given-names></name><name><surname>Fenske</surname><given-names>T.S.</given-names></name><name><surname>Moss</surname><given-names>R.B.</given-names></name></person-group><article-title>DAS181 treatment of severe parainfluenza virus 3 pneumonia in allogeneic hematopoietic stem cell transplant recipients requiring mechanical ventilation</article-title><source>Case Rep Med</source><volume>2016</volume><year>2016</year><fpage>8503275</fpage><pub-id pub-id-type="pmid">26941799</pub-id></element-citation></ref><ref id="bib140"><label>140</label><element-citation publication-type="journal" id="sref140"><person-group person-group-type="author"><name><surname>Colombo</surname><given-names>R.E.</given-names></name><name><surname>Fiorentino</surname><given-names>C.</given-names></name><name><surname>Dodd</surname><given-names>L.E.</given-names></name><name><surname>Hunsberger</surname><given-names>S.</given-names></name><name><surname>Haney</surname><given-names>C.</given-names></name><name><surname>Barrett</surname><given-names>K.</given-names></name></person-group><article-title>A&#x000a0;phase 1 randomized, double-blind, placebo-controlled, crossover trial of DAS181 (Fludase(R)) in adult subjects with well-controlled asthma</article-title><source>BMC Infect Dis</source><volume>16</volume><year>2016</year><fpage>54</fpage><pub-id pub-id-type="pmid">26830468</pub-id></element-citation></ref><ref id="bib141"><label>141</label><element-citation publication-type="journal" id="sref141"><person-group person-group-type="author"><name><surname>Lvov</surname><given-names>D.K.</given-names></name><name><surname>Bogdanova</surname><given-names>V.S.</given-names></name><name><surname>Kirillov</surname><given-names>I.M.</given-names></name><name><surname>Shchelkanov</surname><given-names>M.Y.</given-names></name><name><surname>Burtseva</surname><given-names>E.I.</given-names></name><name><surname>Bovin</surname><given-names>N.V.</given-names></name></person-group><article-title>[Evolution of pandemic influenza virus A(H1N1)pdm09 in 2009-2016: dynamics of receptor specificity of the first hemagglutinin subunit (HA1).]</article-title><source>Vopr Virusol</source><volume>64</volume><year>2019</year><fpage>63</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">31412172</pub-id></element-citation></ref><ref id="bib142"><label>142</label><element-citation publication-type="journal" id="sref142"><person-group person-group-type="author"><name><surname>Cueno</surname><given-names>M.E.</given-names></name><name><surname>Imai</surname><given-names>K.</given-names></name><name><surname>Shimizu</surname><given-names>K.</given-names></name><name><surname>Ochiai</surname><given-names>K.</given-names></name></person-group><article-title>Homology modeling study toward identifying structural properties in the HA2 B-loop that would influence the HA1 receptor-binding site</article-title><source>J&#x000a0;Mol Graph Model</source><volume>44</volume><year>2013</year><fpage>161</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">23831996</pub-id></element-citation></ref><ref id="bib143"><label>143</label><element-citation publication-type="journal" id="sref143"><person-group person-group-type="author"><name><surname>L&#x02019;Vov</surname><given-names>D.K.</given-names></name><name><surname>Burtseva</surname><given-names>E.I.</given-names></name><name><surname>Prilipov</surname><given-names>A.G.</given-names></name><name><surname>Bogdanova</surname><given-names>V.S.</given-names></name><name><surname>Shchelkanov</surname><given-names>M.</given-names></name><name><surname>Bovin</surname><given-names>N.V.</given-names></name></person-group><article-title>[A possible association of fatal pneumonia with mutations of pandemic influenza A/H1N1 sw1 virus in the receptor-binding site of the HA1 subunit]</article-title><source>Vopr Virusol</source><volume>55</volume><year>2010</year><fpage>4</fpage><lpage>9</lpage></element-citation></ref><ref id="bib144"><label>144</label><element-citation publication-type="journal" id="sref144"><person-group person-group-type="author"><name><surname>Sutton</surname><given-names>T.C.</given-names></name><name><surname>Lamirande</surname><given-names>E.W.</given-names></name><name><surname>Bock</surname><given-names>K.W.</given-names></name><name><surname>Moore</surname><given-names>I.N.</given-names></name><name><surname>Koudstaal</surname><given-names>W.</given-names></name><name><surname>Rehman</surname><given-names>M.</given-names></name></person-group><article-title>In&#x000a0;vitro neutralization is not predictive of prophylactic efficacy of broadly neutralizing monoclonal antibodies CR6261 and CR9114 against lethal H2 influenza virus challenge in mice</article-title><source>J&#x000a0;Virol</source><volume>91</volume><year>2017</year></element-citation></ref><ref id="bib145"><label>145</label><element-citation publication-type="journal" id="sref145"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name></person-group><article-title>Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients</article-title><source>Virol J</source><volume>7</volume><year>2010</year><fpage>299</fpage><pub-id pub-id-type="pmid">21047436</pub-id></element-citation></ref><ref id="bib146"><label>146</label><element-citation publication-type="journal" id="sref146"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Shang</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name></person-group><article-title>Subunit vaccines against emerging pathogenic human coronaviruses</article-title><source>Front Microbiol</source><volume>11</volume><year>2020</year><fpage>298</fpage><pub-id pub-id-type="pmid">32265848</pub-id></element-citation></ref><ref id="bib147"><label>147</label><element-citation publication-type="journal" id="sref147"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W.H.</given-names></name><name><surname>Strych</surname><given-names>U.</given-names></name><name><surname>Hotez</surname><given-names>P.J.</given-names></name><name><surname>Bottazzi</surname><given-names>M.E.</given-names></name></person-group><article-title>The SARS-CoV-2 vaccine pipeline: an overview</article-title><source>Curr Trop Med Rep</source><year>2020</year><fpage>1</fpage><lpage>4</lpage></element-citation></ref><ref id="bib148"><label>148</label><element-citation publication-type="book" id="sref148"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Zeng</surname><given-names>H.</given-names></name><name><surname>Gu</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Zheng</surname><given-names>L.</given-names></name><name><surname>Zou</surname><given-names>Q.</given-names></name></person-group><series>Progress and prospects on vaccine development against SARS-CoV-2. Vaccines (basel)</series><volume>vol. 8</volume><year>2020</year></element-citation></ref><ref id="bib149"><label>149</label><element-citation publication-type="journal" id="sref149"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Kream</surname><given-names>R.M.</given-names></name><name><surname>Stefano</surname><given-names>G.B.</given-names></name></person-group><article-title>An evidence based perspective on mRNA-SARS-CoV-2 vaccine development</article-title><source>Med Sci Mon Int Med J Exp Clin Res</source><volume>26</volume><year>2020</year><fpage>e924700</fpage></element-citation></ref><ref id="bib150"><label>150</label><element-citation publication-type="journal" id="sref150"><person-group person-group-type="author"><name><surname>Pawelec</surname><given-names>G.</given-names></name><name><surname>Weng</surname><given-names>N.P.</given-names></name></person-group><article-title>Can an effective SARS-CoV-2 vaccine be developed for the older population?</article-title><source>Immun Ageing</source><volume>17</volume><year>2020</year><fpage>8</fpage><pub-id pub-id-type="pmid">32300370</pub-id></element-citation></ref><ref id="bib151"><label>151</label><element-citation publication-type="journal" id="sref151"><person-group person-group-type="author"><name><surname>Bhattacharya</surname><given-names>M.</given-names></name><name><surname>Sharma</surname><given-names>A.R.</given-names></name><name><surname>Patra</surname><given-names>P.</given-names></name><name><surname>Ghosh</surname><given-names>P.</given-names></name><name><surname>Sharma</surname><given-names>G.</given-names></name><name><surname>Patra</surname><given-names>B.C.</given-names></name></person-group><article-title>Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): immunoinformatics approach</article-title><source>J&#x000a0;Med Virol</source><year>2020</year><pub-id pub-id-type="doi">10.1002/jmv.25736</pub-id><comment>[online ahead of print]</comment></element-citation></ref><ref id="bib152"><label>152</label><element-citation publication-type="journal" id="sref152"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>S.F.</given-names></name><name><surname>Quadeer</surname><given-names>A.A.</given-names></name><name><surname>McKay</surname><given-names>M.R.</given-names></name></person-group><article-title>Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies</article-title><source>Viruses</source><volume>12</volume><issue>3</issue><year>2020</year></element-citation></ref><ref id="bib153"><label>153</label><element-citation publication-type="journal" id="sref153"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>Y.F.</given-names></name><name><surname>Chien</surname><given-names>C.S.</given-names></name><name><surname>Yarmishyn</surname><given-names>A.A.</given-names></name><name><surname>Lin</surname><given-names>Y.Y.</given-names></name><name><surname>Luo</surname><given-names>Y.H.</given-names></name><name><surname>Lin</surname><given-names>Y.T.</given-names></name></person-group><article-title>A&#x000a0;review of SARS-CoV-2 and the ongoing clinical trials</article-title><source>Int J Mol Sci</source><volume>21</volume><issue>7</issue><year>2020</year></element-citation></ref><ref id="bib154"><label>154</label><element-citation publication-type="journal" id="sref154"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>C.</given-names></name></person-group><article-title>Genotyping coronavirus SARS-CoV-2: methods and implications</article-title><source>Genomics</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.ygeno.2020.04.016</pub-id><comment>[online ahead of print]</comment></element-citation></ref><ref id="bib155"><label>155</label><element-citation publication-type="book" id="sref155"><person-group person-group-type="author"><name><surname>Francis</surname><given-names>M.E.</given-names></name><name><surname>McNeil</surname><given-names>M.</given-names></name><name><surname>Dawe</surname><given-names>N.J.</given-names></name><name><surname>Foley</surname><given-names>M.K.</given-names></name><name><surname>King</surname><given-names>M.L.</given-names></name><name><surname>Ross</surname><given-names>T.M.</given-names></name></person-group><series>Historical H1N1 influenza virus imprinting increases vaccine protection by influencing the activity and sustained production of antibodies elicited at vaccination in ferrets. Vaccines (basel)</series><volume>vol. 7</volume><year>2019</year></element-citation></ref><ref id="bib156"><label>156</label><element-citation publication-type="journal" id="sref156"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>P.</given-names></name><name><surname>Yu</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Liang</surname><given-names>L.</given-names></name></person-group><article-title>Highly conserved antigenic epitope regions of hemagglutinin and neuraminidase genes between 2009 H1N1 and seasonal H1N1 influenza: vaccine considerations</article-title><source>J&#x000a0;Transl Med</source><volume>11</volume><year>2013</year><fpage>47</fpage><pub-id pub-id-type="pmid">23433453</pub-id></element-citation></ref><ref id="bib157"><label>157</label><element-citation publication-type="journal" id="sref157"><person-group person-group-type="author"><name><surname>Schaefer</surname><given-names>S.</given-names></name><name><surname>Simon</surname><given-names>M.</given-names></name></person-group><article-title>FluMist: reconsidering the contraindications</article-title><source>Clin Pediatr</source><volume>54</volume><year>2015</year><fpage>1021</fpage></element-citation></ref><ref id="bib158"><label>158</label><element-citation publication-type="journal" id="sref158"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>J.</given-names></name><name><surname>Moore</surname><given-names>D.</given-names></name></person-group><article-title>FluMist vaccine: questions and answers - summary</article-title><source>Paediatr Child Health</source><volume>16</volume><year>2011</year><fpage>31</fpage><pub-id pub-id-type="pmid">22211071</pub-id></element-citation></ref><ref id="bib159"><label>159</label><element-citation publication-type="journal" id="sref159"><person-group person-group-type="author"><name><surname>Grohskopf</surname><given-names>L.A.</given-names></name><name><surname>Sokolow</surname><given-names>L.Z.</given-names></name><name><surname>Broder</surname><given-names>K.R.</given-names></name><name><surname>Walter</surname><given-names>E.B.</given-names></name><name><surname>Bresee</surname><given-names>J.S.</given-names></name><name><surname>Fry</surname><given-names>A.M.</given-names></name></person-group><article-title>Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices - United States, 2017-18 influenza season</article-title><source>MMWR Recomm Rep (Morb Mortal Wkly Rep)</source><volume>66</volume><year>2017</year><fpage>1</fpage><lpage>20</lpage></element-citation></ref><ref id="bib160"><label>160</label><element-citation publication-type="journal" id="sref160"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>N.J.</given-names></name><name><surname>Plosker</surname><given-names>G.L.</given-names></name></person-group><article-title>Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus</article-title><source>BioDrugs</source><volume>22</volume><year>2008</year><fpage>279</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">18778110</pub-id></element-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgements</title><p>Chungen Pan was supported by a grant from the <funding-source id="gs1">Panyu Innovation and Entrepreneurship Leading Team</funding-source> Project (2017-R02-4). Shuwen Liu was supported by <funding-source id="gs2">Major scientific and technological projects of Guangdong Province</funding-source> (2019B020202002), <funding-source id="gs3">Chinese Academy of Traditional Chinese Medicine</funding-source> (ZZ13-035-02) and <funding-source id="gs4">Evidence based capacity building project of traditional Chinese Medicine</funding-source> (2019XZZX-LG04).</p></ack></back></article>